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Abstract
Type-1 diabetes (T1D) is a chronic metabolic autoimmune disease where the patient's
immune system destroys insulin-producing β-cells in the islet of Langerhans. The current treatment
option is through frequent administration of exogenous insulin, where the patients must closely
monitor the dosage. Patients often need islet transplantation when the β-cell destruction worsens,
and the body cannot utilize exogenously administrated insulin. Islet transplantation is a form of cell
therapy that could restore endogenous insulin production. However, this method has several
drawbacks, including low survival of functional islets and allograft tissue immunogenicity. A
recently emerging tissue engineering approach can offer a possible solution to address the
limitations of islet transplantation. A 3D structure fabricated by simultaneously printing various
cell types could improve the survival and function of islet grafts by providing revascularization and
immune protection.
This project focused on developing inks suitable for simultaneously printing multiple cell
types in the form of core and shell coaxial channels. The shell ink was composed of gelatin
methacryloyl (GelMA), gelatin, and alginate optimized to improve printability at room temperature.
The core ink was composed of GelMA and gelatin. The 3D constructs were fabricated with the
customized Dual Ink Co-axial Bioprinter (DICAB) manufactured in Translational Research
Initiative for Cell Engineering and Printing (TRICEP) for this project. The 3D constructs printed
with the core and shell inks showed structural stability over four weeks.
Additionally, a controlled growth factor release method was explored to improve the
biological activity of the inks. For this purpose, vascular endothelial growth factor-A165 (VEGFA165) laden PLGA microspheres were fabricated using a double emulsion method. The release
profile of VEGF-A165 was established from the 3D constructs where the microspheres were
incorporated within the core channel. The study time for this experiment was four weeks. However,
the result of VEGF-A165 laden PLGA microspheres was not optimal for the project therefore,
future experiments will explore alternative ways to improve the biological properties of the inks.
Further studies are also required for in vitro culture of umbilical vein endothelial cells (HUVEC)
to examine the angiogenic effects of released VEGF-A165.
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1. Introduction
1.1. A summary of Type 1 Diabetes (T1D), current diabetics treatment, and challenges
Type 1 Diabetes (T1D) is an autoimmune disease usually diagnosed in early childhood and requires
lifelong management of symptoms. T1D effects a small segment (5-10%) of the whole diabetic population,
and the occurrences are increasing worldwide at a rate of approximately 3% every year [1]. T1D is usually
diagnosed in childhood with symptoms of polyuria (excessive urine) caused by polydipsia (excessive
thirst), weight loss, and in severe cases, ketoacidosis [2]. However, T1D occurrences in adulthood are
challenging to interpret as the adults do not show the classic symptoms observed in children. Moreover, as
the susceptibility to type 2 diabetes (T2D) increases with age, sometimes a diagnosis of T1D is interpreted
as T2D in adults [3]. More than 4% of T1D occurrences are reported to be diagnosed after the age of thirty,
a study reported by UK Biobank [3].
The pancreas is a multi-function organ that regulates energy and metabolic function by secreting digestive
enzymes and pancreatic hormones. It is located behind the stomach in the abdominal cavity. The primary
function of the pancreas is to release digestive enzymes, while a tiny portion of the pancreas, 1-2% by
volume, secretes pancreatic hormones [4]. Among the pancreatic hormones, insulin and glucagon are the
primary hormones produced by β-cells and α-cells, representing around 65-80% and 15-20% of the total
islet cells, respectively [5]. Figure 1 presents the structure of the pancreas [6].

Figure 1. Anatomy of the pancreas in the human body. The acinar cells produce digestive enzymes
that releases it into the body via pancreatic duct. The islet of Langerhans is cluster of cells consist
of alpha, beta and delta cells. They secrete pancreatic hormones such as insulin and glucagon
directly into the capillary network. Adapted from [6].

Glucagon responds to low blood glucose levels by simulating the glucose formation within the liver cells,
whereas insulin decreases the blood glucose level [7]. Together, they maintain the narrow blood
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concentration of 4-6 mM, called glucose homeostasis [5]. In order to maintain glucose concentration in
blood circulation, the pancreas works in a highly sophisticated manner. There is emerging evidence that
the pancreatic hormones are regulated by the pancreas and the interplay between the muscle and adipose
tissues, gut, brain, and liver [5]. Individuals may suffer from metabolic disorders such as T1D if their
pancreatic hormone regulation is disrupted or imbalanced.
Prior to the treatment of insulin, which started in 1921, the only method to treat T1D was believed to be
through the “Eskimo diet,” where patients need to consume less than 500 calories per day [8]. As a result,
the patients often die from either diabetic coma or other complications. The discovery of insulin has
transformed the treatment of T1D, previously known as a terminal disease with an average lifespan of 1.4
years after the initial diagnosis, into a manageable disease [8]. Injection of exogenous insulin remains the
mainstream treatment for T1D. However, achieving and maintaining an optimal level of glycemic control
continues to be a challenge to meet individual patients’ specific needs and life style. Maintaining glycemic
control requires multiple doses of insulin throughout the day with diverse types of insulin. For example,
short-acting insulin keeps the basal level of blood glucose concentration and rapid-acting insulin helps the
body to decrease the glucose associated with carbohydrate consumption [1]. In addition, adjustment of
insulin dosage is often required. These adjustments significantly affect the patient’s quality of life and
increase costs for the patient’s healthcare.
Further, exogenous insulin delivery differs from normal physiological homeostatic regulation;
hypoglycemia (low blood glucose level) is commonly developed in T1D patients who receive insulin
treatment [9]. Alternative options such as solid pancreas transplantation or islet transplantation procedures
were proposed to address the clinical shortcomings related to insulin treatments. Solid-organ pancreas
transplantation is a major surgery associated with high-risk complications [10]. To be considered for
pancreas procurement, the donor should be between 20 years to 50 years old with a Body Mass Index
(BMI) less than 30 kg/m2 and no underlying chronic disease at the time of the organ donation [10].

Figure 2. Schematic illustration for general procedure of islet
transplantation. Adapted from [11] .
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Islet transplantation is a significantly safer procedure with minimal side effects than solid-organ pancreas
transplantation. Compared to solid-organ pancreas transplantation, donors with higher BMI are often
accepted for islet transplantation procedures [10]. Figure 2 presents the schematic illustration for the islet
transplantation procedure [11]. The islet transplantation process involves isolating and purifying the islet
from the cadaveric donor pancreas and its infusion into the patient's portal vein [10]. The rationale behind
this procedure is that transplanted islets will start secreting insulin without requiring exogenous insulin.
Significant success with islet transplantation came in 1990 when the Edmonton protocol was adapted to a
procedure for patients to gain glycaemic controls over sometime [10]. From 1990 to 2001, approximately
267 islet transplantations were performed with an average success of 8.2% retaining total insulin
independence for more than a year [12]. The long-term correction of glycaemic control has not been
achieved by exogenous insulin treatment types, including continuous glucose monitoring and insulin
pumping technologies [10]. Although the clinical outcome of islet transplantation improved patients’
quality of life, this method has its challenges. First, a large number of islets are required for the islet
transplantation procedure. In general, the minimum islet mass required for transplantation is about >5000
islet equivalent (IEQ)/kg body mass [10, 12]. This often requires multiple donors, which are already limited
in numbers. Second, maintaining the islet function post-transplantation is difficult. The islets have a highly
vascular structure that receives about 10% of the pancreas blood supply despite comprising only 1-2% of
the whole pancreas volume [4]. During the preparation of islets for transplantation, the pancreas goes
through multiple steps of isolation processes involving enzymatic digestion, mechanical shear, and
purification, which alters the islets’ native vascular structure [10]. Without adequate vascular structure, the
islets cannot function properly, leading to premature graft failure. It is assumed that approximately 60-80%
of the islet grafts undergo apoptosis within days post-transplantation [4]. Third, immune rejection and
reoccurrence of autoimmunity are typical for the recipients. A study by Evgenov et al. (2006) used a
contrast agent to image the immune rejection of transplanted islets in vivo. The finding suggested that
immune rejection starts after the islet transplantation and further contributes to early graft failure [13].
Further, life-long immune suppression can cause potential organ damage and other complications.
Extensive research had been done on encapsulation to protect islet grafts from immune-mediated attacks
and/or provide oxygen to prevent hypoxia. For example, Soon-Shiong et al. (1993) demonstrated that
intraperitoneal injection of encapsulated islets in alginate was viable for 726 days with insulin
independence for 172 days in dogs [14]. Barkai et al. (2013) developed a subcutaneous implantable bioartificial pancreas (β-air) [15]. This device is composed of immobilized islets in alginate hydrogel, a gas
chamber and permeable membrane, a mechanical support, and an external membrane. The primary
function of the device is to keep the islets oxygenated through a subdermal access port. The implanted
device in the diabetic rats showed a normalized glucose index up to six months [15].
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1.2. A glimpse on tissue engineering
Tissue engineering and regenerative medicine (TERM) is an emerging multidisciplinary approach where
nanotechnology, cell biology, functional material engineering, and biofabrication are applied to create a
bio-artificial substitute for organs and tissues. The focus of the tissue engineering discipline is to create an
artificial extra-cellular matrix, also known as scaffolds, that, in combination with living cells to form tissue
surrogates. The scaffold material, cell types, and growth factors are crucial elements to determine tissue
engineering functions [16].

Figure 3. Bottom-up and top-down fabrication techniques for tissue
engineering. The top-down fabrication approach is designed to
culture cells on the already fabricated scaffolds while the bottomup fabrication approach is designed to use assemblies of cells to
fabricate the scaffolds. Adapted from [17].

The extra-cellular matrix supports the cells by providing (i) physical support, (ii) mechanical stability, (iii)
storage and release of the growth-stimulating factors, and (iiii) regulation of the cellular activities. The
mechanical properties of the tissue of interest directly influence the selection of the scaffold’s material.
For example, ceramics and their composites are typically used to model stiff and load-bearing hard tissues,
while hydrogels are used to model soft tissues. For the fabrication of the scaffolds, two types of approaches
are employed, top-down and bottom-up. The top-down fabrication approach is implemented by seeding
cells on the already fabricated scaffolds, while the bottom-up fabrication approach is implemented by
assembling cells by means of printing, aggregating, and in the form of sheets to create the engineered
tissues. Figure 3 presents the visual representation of the bottom-up and the top-down fabrication
techniques for tissue engineering approaches [17].

13

Examples of top-down fabrication (traditional approaches) are solvent casting-particle leaching, freezedrying, and electrospinning, shown in Figure 4 [18]. The solvent casting-particle leaching technique is
relatively simple and can create scaffolds with controlled composition. The procedure begins with
dissolving the polymer in an organic solvent where it is mixed with salt particles. The organic solvent
evaporates as the polymer hardens. The hardened 3D scaffold is then washed with water to remove the salt
particles resulting in porous scaffolds. (Figure 4A). However, the limitations of this technique are hard to
control pore size, the interconnectivity of the pores, and the use of an organic solvent which restricts the
inclusion of cells. The freeze-drying process starts with freezing the organic solvent and polymer blend,
creating frozen 3D polymer aggregates with solvent ice crystals. The frozen solvent ice crystals are then
evaporated by sublimation (Figure 4B).

Figure 4. Examples of top-down fabrication approaches for creation of scaffolds. (A) Solvent castingparticle leaching method. (B) Freeze-drying method. (C) Electrospinning method. Adapted from [18].

The limitations of this technique are the time consumption and difficulty controlling the pore size.
Electrospinning is one of the most widely used techniques in tissue engineering. It is an inexpensive yet
simple technique that can create a scaffold with a large surface area for cell attachment. The fabrication
technique uses an external field to draw charged polymer threads from a capillary tube into the collector
plate (Figure 4C). The limitations of this technique are the use of an organic solvent that is harmful to cells
and the imprecise microarchitecture of the constructs [18]. The success of the top-down fabrication method
is limited in many ways despite the diverse approaches. First, the scaffolds show limited revascularization
progress because of their bulk microarchitecture and lack of growth factor incorporation in the scaffold.
Second, uniform cell distribution is difficult to achieve due to the scaffold’s non-uniform pore size, and
often the seeded cells form a thin peripheral layer on the surface. Third, it is difficult to accommodate
multiple cell types within one structure in a controlled manner [17].
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The bottom-up fabrication approaches in tissue engineering rely on assembling smaller, usually
microscopic components into a macroscopic scaffold [19]. The rationale behind this approach is to mimic
the extra cellular environment more closely by integrating various bioactive molecules or cells into the
scaffolds during the assembly process. The emergence of tissue engineering in medicine can be dated back
to the early 1990s, and its potential has begun to attract more researchers in the last twenty years. For
example, the total number of bone tissue engineering studies ever published through the year 2000 was
340, and by the year 2013, the total number of these studies increased to over 2000 [20]. Pancreatic tissue
engineering studies have also increased throughout the years. For example, a recently published systematic
review for pancreatic tissue engineering reported that over the last ten years, approximately 341 papers
were published about islet and tissue engineering [21]. These papers included 197 studies that used
experiment-based approaches on insulin production cells. The common fabrication techniques employed
for these studies were droplet microencapsulation, syringe-based droplet extrusion, solvent casting-particle
leaching, electrospinning, and 3D bioprinting [21].

1.3. Bioprinting for pancreatic tissue engineering
Basic bioprinting techniques
3D bioprinting is an example of bottom-up fabrication approaches in tissue engineering. In general, cells
and biomaterials are deposited into small units of micrometer-scale to create a scaffold with great precision.
This allows several advantages over the top-down fabrication approaches, including uniform cell
distribution, incorporation of bio-active materials, and the ability to include multiple cell types in a
spastically controlled manner. These advantages are attributed to the development of multiple types of
bioprinting techniques. Currently, there are four main techniques widely employed in 3D bioprinting:
inkjet, extrusion, laser-assisted, and extrusion-based bioprinting (Figure 5) [22].

Figure 5. Schematic diagram for bioprinting methods. (A) Inkjet bioprinter produces droplets
thermally or piezoeletrically. (B) Microextrusion bioprinter produces continuous filament
through pneumatic or mechanical (piston or screw) dispensing system. (C) Laser-assisted
bioprinter uses laser pulse to generate pressures through the absorbing layer causing the cell
containing biomaterials to fall on the substrate. Adapted from [22].
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Inkjet bioprinting is one of the first methods developed for bioprinting and is similar to commercial 2D
printing. This fabrication process involves squeezing the hydrogel polymer in the form of droplets from a
thermo or piezoelectric actuator (Figure 5A) [22]. However, the inkjet-based bioprinting method does not
work well with viscous hydrogel or hydrogels with high cell density [22]. The light-assisted bioprinting
method uses a laser pulse to deposit biomaterials onto a substrate. When the laser shoots the donor slide,
the energized absorbing layer coated underneath produces a high-pressure bubble which causes the
hydrogel on the bottom of the donor slide to fall as droplets onto the substrate (Figure 5C). Since there is
no direct contact between the dispenser and the cell incorporated hydrogel, the cells do not experience any
mechanical stress, therefore, improving the cell viability (>95%) [22] . However, the cost-effectiveness of
light-assisted bioprinting is higher than other bioprinting techniques, which restricts the widespread usage
[22]. The extrusion printing technique is a modified version of the ink-jet printing technique where a
continuous force is applied on the dispenser, thus creating a cylindrical-shaped continuously extruded
hydrogel (Figure 5B). Although extrusion-based bioprinting shows lower resolution compared to other
bioprinting techniques, it offers the ability to print high-density encapsulated cells [23]. The extrusionbased fabrication technique is simple and can print different types of viscous hydrogels between 30 mPa/s
to 6 x 107 mPa/s as well as cell aggregates [22, 23]. Many commercially available bioprinters, such as
Novogen (Organova) and Bioplotter (EnvisionTEC), are based on the extrusion bioprinting method.
However, there is a concern over the cells experiencing high mechanical shear stress during the fabrication
process [22]. For this reason, one of the requirements of the biomaterials for extrusion-based bioprinting
is shear-thinning property which could potentially affect the choice of biomaterials.
Hydrogels as Biomaterials
The intended application of 3D bioprinting, for example, for bone regeneration, pancreas development, or
wound healing, will directly influence the material selection and technique employed for fabrication. The
term biomaterial is broadly used in tissue engineering and represents materials selected for creating the
extra cellular matrix-like environment. Hydrogels are a soft type of biomaterials that are extensively
studied for the fabrication of cell-supporting constructs. Hydrogels are hydrophilic polymers with
extensive mechanical tunability and an ability to retain their 3D structures in a hydrated state. Based on
their origins, hydrogels are divided into biological or synthetic polymers [22]. Biologically derived
hydrogels offer a superior advantage in terms of mimicking the composition of natural tissues. However,
biologically derived hydrogel polymers often lack appropriate mechanical strength, while synthetic
hydrogel offers better mechanical and chemical properties. The synthetic and naturally derived hydrogels
may be combined to create hybrid hydrogels to support the requirements of the intended applications [16].
A systematic review on pancreatic tissue engineering reported that alginate was the choice of biomaterial
for 42 studies, collagen for 27 studies, gelatin for 12 studies, and fibrin for 11 out of 197 studies [21]. For
example, a study conducted by Marchioli et al. (2015) used 4/5% (w/v) alginate/gelatin hydrogel
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containing INS1E cells (β-cell line derived from rat insulinoma) to create a 3D porous scaffold via 3D
bioplotter (SysENG, Germany) [24]. While the alginate/gelatin hydrogel accommodated the high viability
of the INS1E cells (more than 90% cell viability on day 21), the viscous nature of the hydrogel caused
insufficient diffusion of glucose and low metabolic activity [24]. Another study by Duin et al. (2019) used
3/9% (w/v) alginate/methylcellulose for fabrication of islet-laden 3D scaffolds [25]. The islets
encapsulated scaffolds preserved the islets’ morphology and localization of α and β-cells. The cells were
also viable (80%) for seven days. Further, the encapsulated islets also responded to glucose stimulation for
up to seven days [25].
Coaxial bioprinting
One of the attractive features of 3D bioprinting is its versatile option for adding complexity. Hybrid
biomaterials and hybrid printing techniques are often employed to create 3D constructs that closely mimic
the extra-cellular matrix. One example is the coaxial extrusion-based bioprinting technique. The capability
of using two types of biomaterials in the form of core and shell provides great flexibility on the choice of
biomaterials, growth-stimulating hormones, and cell types. This technique is already being applied to
several studies. For example, Hong et al. (2019) fabricated cell-laden vascular constructs using the coaxial
bioprinting method [26]. The shell bioink was prepared by incorporating HUVEC in GPT (gelatin-PEGtyramine), while the core bioink was prepared by dissolving 5% (w/v) gelatin in PBS that contained 1%
H2O2, shown in Figure 6A. The purpose of H2O2 was to help regulate endothelial cell proliferation [26].
The resulting cell-laden constructs showed HUVEC spreading along with the tubular shape on day 8,
shown in Figure 6B [26].
In another study, Dai et al. (2017) employed the coaxial fabrication method for modeling a 3D cancer
environment [27]. The shell bioink, composed of alginate, gelatin, and thrombin which acted as a scaffold
and high-density cell suspension (glioma stem cells and mesenchymal stem cells), was loaded in the core,
shown in Figure 6C [27]. GFP-expressing mesenchymal stem cells and RFP-expressing glioma cells were
utilized to visualize the interaction between the glioma-stroma cells, shown in Figure 6D and Figure 6E,
respectively. By day 7, both cell types were integrated and formed fibers, shown in Figure 6F. The resulting
cell-laden constructs showed the interaction between the glioma-stroma cells, which is typically observed
in solid tumors [27].
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Figure 6. Examples of coaxial bioprinting strategies. (A) Coaxial fabrication schematic illustration for
vascular constructs. (B) The morphology of HUVEC (encapsulated in the shell) on day 2 and day 8. Scale
bar 200 µm. Adapted from [26]. (C) Coaxial fabrication schematic illustration for modelling 3D cancer.
(D) GFP expressing mesenchymal stem cells on day 7. (E) RFP-expressing glioma stem cells on day 7. (F)
Integrated fiber of GFP-expression mesenchymal and RFP-expressing glioma cells on day 7. Scale bar 100
µm. Adapted from [27].
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2. Project concept
Scope of this study
This project focused on developing and optimizing bioinks suitable for coaxial extrusion bioprinter and
was part of an ongoing joint research project between the University of Adelaide and Wollongong.
Figure 7 presents the schematic illustration for the proposed bioprinting approach.

Figure 7. Schematic illustration of the coaxial 3D constructs containing the core and shell bioinks
together with growth factory delivery system.

The bioprinter used for this study, the customized Dual Ink Co-axial Bioprinter (DICAB), was
manufactured in the Translational Research Initiative for Cell Engineering and Printing (TRICEP)
Wollongong, Australia. The aim was to formulate core and shell bioinks with biologically derived
polymers optimized to fabricate structurally stable 3D constructs. Furthermore, a controlled growth
factor delivery system was also explored to enhance the biological property of the core and shell
bioinks. The specific objectives of this study can be described as:
•

To establish a protocol for room temperature printable bioinks

•

To establish experimental set-up for printability assessment for the customized coaxial bioprinter

•

To establish growth factor release study from the microsphere-laden 3D constructs

This thesis project was written in three sections where the main components of the bioinks, the synthesis
of gelatin methacryloyl (GelMA) and its characterization, and the fabrication of microspheres were
discussed first. The performance assessment of the customized bioprinter and the rheological
characterization of the bioinks were discussed second. The fabrication of the 3D constructs and their
physiochemical properties assessment were discussed third. For growth factor delivery, the Vascular
Endothelial Growth Factor-A165 (VEGF-A165) was chosen in this study to stimulate the
revascularization progress. The optimal concentration of VEGF-A165 for 3D angiogenic studies was
reported to vary between 25 ng/mL to 100 ng/mL [28-31]. The release profile of VEGF-A165 was
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established from microsphere-laden 3D constructs and compared to the optimal VEGF-A165
concentration range for stimulating revascularization in 3D angiogenic studies. The islet and isletrelated cells encapsulation to the room temperature printable ink and cell assays related to immune
protection efficacy and viability was demonstrated elsewhere [32]. Figure 8 presents the sequential
experimental setup and associated experiments.

Figure 8. The sequence of experimental setup for development of the microsphere-laden 3D coaxial
constructs fabricated with room temperature printable inks using a customized coaxial bioprinter.

Objective 1: Fabrication of the bioink components
•

Gelatin methacryloyl (GelMA), the main component of the bioink, was synthesized by
methacryloylation of the gelatin. The degree of modification was determined by a ninhydrin reaction
test.

•

Microspheres containing vascular endothelial growth factor-A165 (VEGF-A165) were fabricated with
poly-lactic-co-glycolic acid (PLGA) polymer using a double emulsion method. A small batch of
microspheres was fabricated with differing inner water formulations, polymer concentrations, and
outer water volume while keeping the other fabrication parameters unchanged to assess the parameters
influencing the VEGF-A165 release kinetics and microsphere size distribution. Further, the effect of
the increased VEGF-A165 load was also evaluated.

Objective 2: Printability assessment of the customized bioprinter and the development of inks for
coaxial printing
•

The lutrol®-F127 polymer was employed for performance validation of the DICAB via the following
experiments: software and hardware communication, extrusion rate measurement, core and shell
extrusion ratio, and the capability of printing multiple layers. First, the software and hardware
communication were assessed through the bioprinter’s movement in the three-dimensional space and
extrusion consistency. Second, the extrusion rate and core|shell extrusion ratios were measured by
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varying printing parameters. Third, the bioprinter’s capability to print multiple layers was tested by
fabricating multiple-layer 3D scaffolds.
•

The previously established ink for this project by Liu et al. [33], composed of 2/7.5% (w/v)
alginate/GelMA, was incorporated with the series of gelatin concentrations to improve printability at
room temperature. The printability of the gelatin incorporated alginate/GelMA inks was tested by the
bioprinter.

•

The rheological tests were done on the alginate/gelatin/GelMA and alginate/GelMA inks to study the
effect of gelatin incorporation on the flow behavior. First, oscillatory temperature sweep and time
sweep tests were performed on the inks to determine sol-gel transition points. A rotational shear
viscosity test was employed to assess the shear-thinning behavior. An oscillatory step strain test was
employed to evaluate the inks’ self-recovery. An oscillatory frequency and strain sweep test were
employed to determine the inks’ linear-viscoelastic (LVE) region. Regarding the core ink formulation,
the alginate component of alginate/gelatin/GelMA ink was replaced with CaCl2 to enhance the coaxial
resolution through physical crosslinking.

Objective 3: Evaluation of 3D fabricated constructs
•

The mechanical strength of the 3D constructs fabricated with core and shell inks was evaluated by a
uniaxial compression test, and the rehydration rate was evaluated by a water uptake test.

•

The release profile of the VEGF-A165 laden microsphere incorporated in the 3D constructs was
evaluated in vitro for four weeks.
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3. Materials and Method
3.1. Materials
Gelatin (porcine skin, gel strength 175, Type A, Sigma-Aldrich), methacrylic anhydride (MW=154.16),
ninhydrin reagent, fluorescein isothiocyanate (FITC), rhodamine B isothiocyanate, lutrol F-127, alginate
(medium viscosity), gelatin (gel strength 300, type A), poly (vinyl alcohol) (MW=31k-50k, 98-99%
hydrolyzed), and lithium-phenyl-2,4,6-trimethyl-benzoyl phosphinate (LAP) were purchased from SigmaAldrich (USA). The enzyme-linked immunosorbent assay (ELISA) and recombinant human vascular
endothelial growth factor-A165 (VEGF-A165) were purchased from R&D Systems (USA).

3.2. Synthesis of Gelatin methacryloyl (GelMA)
Gelatin was sterilized under UV light in the laminar hood for 20 minutes (RFC cabinets, AES
environmental) then dissolved in 10% (w/v) phosphate buffer saline (PBS) at 50°C for 1 hour. For
methacryloylation of gelatin, the methacrylic anhydride was added dropwise to pre-warmed gelatin
solution at 50°C with a stirring speed of 600 rpm until the concentration reached 7.4% (v/v). The reaction
was left to continue for 4 hours at 50°C with an 800 rpm stirring speed and terminated by adding 5M NaOH
dropwise until the pH was neutralized at 7.4. In addition, 1% (v/v) chloroform was added to GelMA
solution and dialyzed against distilled water for seven days at 37°C using cellulose membrane (MW cutoff: ~12kDa, Sigma-Aldrich). Finally, the dialyzed GelMA solution was lyophilized (Martin Christ,
ALPHA 2-4 LDplus) for seven days until the white porous foam was formed and stored at -20°C. The
GelMA synthesis was performed inside a laminar hood under sterile conditions.

3.3. Degree of Modification (DoM) of GelMA by ninhydrin assay
Ninhydrin (2,2-dihydroxyindane-1,3-dione) assay is a colorimetric reaction between primary and
secondary amines to produce a Ruhemann’s purple chromophore. The absorbance of Ruhemann’s purple
produced by GelMA samples (40 mg/mL) was compared with the absorbance of Ruhemann’s purple
produced by unmodified gelatin solutions to determine the degree of modification.
First, 40 mg/mL GelMA sample solutions were prepared in sterile deionized water. Second, unmodified
gelatin solutions with concentrations ranging from 0 mg/mL to 40 mg/mL were prepared in sterile
deionized water. Next, 50 µl of ninhydrin reagent was added to each 100 µl solution, including the GelMA
samples, and the reaction was allowed to run for 12 minutes at 50°C in a water bath. After the reaction, the
solutions were allowed to cool down to room temperature for 20 minutes. Then 100 µl of each solution
was added into a 96 well-plate, and its absorbance was measured at 570 nm using a microplate reader
(BMG Labtech, Germany). A standard curve was established by plotting the absorbances of Ruhemann’s
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purple produced by unmodified gelatin against its concentrations at 40, 20, 10, 5, 2.5, 0 mg/mL. The
degree of modification of GelMA was determined by the following equation.
𝐃𝐃𝐃𝐃𝐃𝐃 = 𝟏𝟏𝟏𝟏𝟏𝟏% −

𝐨𝐨𝐨𝐨𝐨𝐨𝐨𝐨𝐨𝐨𝐨𝐨𝐨𝐨𝐨𝐨 𝐆𝐆𝐆𝐆𝐆𝐆𝐆𝐆𝐆𝐆 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜
∗ 𝟏𝟏𝟏𝟏𝟏𝟏%
𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭𝐭 𝐆𝐆𝐆𝐆𝐆𝐆𝐆𝐆𝐆𝐆 𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜𝐜

(1)

3.4. Preparation of fluorescently labeled GelMA
Synthesis of GelMA-FITC

Briefly, 1 g GelMA was dissolved in 100 mL of 0.1 M freshly made sodium bi-carbonate buffer. Next, 10
mg fluorescein isothiocyanate (FITC) was dissolved in 10 mL DMSO and added to the GelMA solution
uniformly, and the labeling reaction was allowed to continue overnight with a low stirring speed of 400
rpm. The following day, 1% (v/v) of chloroform was added to the fluorescently labeled GelMA-FITC to
prevent bacterial growth, and the solution was dialyzed against distilled water for fourteen days at 37ºC
using cellulose membrane (MW cut off: ~ 12kDa, Sigma-Aldrich). The dialyzed GelMA-FITC solution
was lyophilized (Martin Christ, ALPHA 24 LDplus) for seven days until the porous foam was formed and
stored at -20°C.
Synthesis of GelMA-Rhodamine B
Briefly, 1 g GelMA was dissolved in 100 mL of 0.1 M freshly made sodium bi-carbonate buffer. Next, 10
mg rhodamine B was dissolved in 10 mL DMSO and added to the GelMA solutions uniformly, and the
labeling reaction was allowed to continue overnight with a low stirring speed of 400 rpm. The following
day, 1% (v/v) of chloroform was added to the fluorescently labeled GelMA-Rhodamine to prevent bacterial
growth, and the solution was dialyzed against distilled water for fourteen days at 37ºC using cellulose
membrane (MW cut off: ~ 12kDa, Sigma-Aldrich). The dialyzed GelMA-Rhodamine solution was
lyophilized (Martin Christ, ALPHA 2-4 LDplus) for seven days until the porous foam was formed and
stored at -20°C.

3.5. Fabrication of VEGF-A165 incorporated Poly (Lactic-co-Glycolic Acid)
microspheres
Microsphere fabrication method
The microspheres were fabricated using a modified double emulsion water-in-oil-in-water (w1-o-w2)
method [34]. Figure 9 presents the schematic illustration of a double emulsion method for microsphere
fabrication [34]. Briefly, the inner water phase (w1) contained the VEGF-A165 was emulsified with the
organic phase (o) by vortex for 30 seconds. The organic phase (o) was composed of polylactic-co-glycolic
acid (PLGA) dissolved in dichloromethane (DCM). This phase created the first water-in-oil (w1-o)
emulsion. The resulting w1-o emulsion was poured into a 2.5% (w/v) polyvinyl alcohol (PVA) solution
and homogenized for another 60 seconds to create the secondary water-in-oil-in-water (w1-o-w2)
emulsion. The solution was then directly added to 100 mL of 0.5% (w/v) PVA solution for 2 minutes at
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1500 rpm, then continued stirring for another 2 hours at 800 rpm to evaporate the organic solvent. The
hardened microspheres were centrifuged (3000 ˟ g, 5 minutes) and washed with distilled water three times
to remove free PVA. The washed microspheres were re-suspended in 5 mL distilled water and frozen
overnight before being lyophilized for three days. The microspheres were then stored at -20°C.

Figure 9. Schematic illustration of double emulsion method for microsphere fabrication. The inner aqueous
phase containing the growth factor emulsified with the organic phase where it created the water-in-oil
emulsion (w1-o). The resulting (w1-o) emulsion was emulsified again with the outer water phase, which
created the water-in-oil-in-water (w1-o-w2) emulsion. The second emulsion was added to the PVA solution
to harden the microspheres and evaporate the organic solvent. Adapted from [34].

Prior to selecting the final fabrication parameters, first, the following were investigated for their effect on
microsphere morphology and growth factor release rate: inner water phase (w1), oil phase (o), and outer
water phase (w2). A small batch of microspheres was fabricated by using the fabrication method. The
investigated parameter conditions are outlined in Table 1.
Table 1. List of parameters change for microsphere fabrication
Parameters change

Detailed explanation

Inner water phase (w1):
solvent concentration
change

0.1% vs. 1% (w/v) of PBS and BSA effect on microsphere morphology and VEGFA165 release profile over four weeks

The organic phase (o):
PLGA concentration
change
Outer water phase (w2):
volume change

10% vs. 15% (w/v) PLGA concentration effect on microsphere morphology and
VEGF-A165 release profile over four weeks
1/2 vs. 1/10 (o/w2) ratio change and its effect on microsphere morphology and
VEGF-A165 release profile over four weeks

The microsphere morphology and growth factor release profile
The morphology of the VEGF-A165 incorporated PLGA microspheres was captured by Leica M205A
microscope (Leica Microsystems, Germany), and the particle diameters were measured by ImageJ
software. The microsphere size distribution graph was constructed by plotting the number of measured
particles’ diameters as frequency (y-axis) against its corresponding diameter range (x-axis). In vitro release
of the VEGF-A165 was established by placing approximately 5 mg of microspheres into a centrifuge tube
filter (Corning, USA) containing 800 µl of 1% BSA (w/v) in PBS. The samples were incubated at 37°C
for four weeks. The released amount of VEGF-A165 was collected by centrifuging the samples on days 1,
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3, 7, 10, 14, 18, 21, 24, 28, and the supernatants were stored at -20°C. The pellets were then re-suspended
with fresh 800 µl of 1% BSA (w/v) in PBS on each time-point. The released VEGF-A165 amount was
quantified using an enzyme-linked immunosorbent assay (ELISA) following the manufacturer’s protocol.
Briefly, 100 µl of released VEGF-A165 was pipetted into capture antibody-coated 96-well plates in
duplicates and incubated at room temperature. After 2 hours, the wells were washed three times with 200
µl of wash buffer, then 100 µl of detection antibody was pipetted into each well and incubated at room
temperature. After 2 hours, the wells were washed three times with 200 µl of wash buffer, then 100 µl of
working dilution of streptavidin-HPR was pipetted into each well and incubated at room temperature. After
20 minutes, the wells were washed three times with 200 µl of wash buffer, then 100 µl of substrate solution
was pipetted into each well and further incubated for 20 minutes at room temperature. The reaction was
terminated by adding 50 µl of stop solution, and the optical density of the wells read at 450 nm (Bio-Rad
Model 680). The net VEGF-A165 release was first calculated according to the standard curve equation
created from the experiment. The net VEGF-A165 release was quantified into nanogram VEGF-A165
release per microgram of microsphere by the following equation:
𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 − 𝐴𝐴 (𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑛𝑛𝑛𝑛 𝑝𝑝𝑝𝑝𝑝𝑝 𝑚𝑚𝑚𝑚 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚ℎ𝑒𝑒𝑒𝑒𝑒𝑒) =

The data was represented in mean±standard deviation (n=3).

𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 − 𝐴𝐴𝑛𝑛𝑛𝑛𝑛𝑛 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚ℎ𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒

(2)

3.6. Preparation of the inks
Shell ink preparation
The ink formulation was prepared by first sterilizing the 0.2 g alginate under UV light in the laminar hood
(RFC cabinets, AES environmental) for 20 minutes and dissolving it in sterile 10 mL of PBS at 37°C
overnight. Second, 0.75 g GelMA was added to the 2% (w/v) alginate solution and incubated at 37°C for
an additional 16 hours with occasional stirring to achieve a final concentration of 2/7.5% (w/v)
alginate/GelMA solution. In addition, gelatin (porcine skin, gel strength 300, Type A, Sigma-Aldrich) was
added to the alginate solutions in various concentrations (2.5%, 3.5%, or 5% w/v) together with GelMA to
create various concentrations of gelatin incorporated alginate/GelMA solutions.
Core ink preparation
Gelatin (porcine skin, gel strength 300, Type A, Sigma-Aldrich) mass of 0.35 g was sterilized under UV
light in the laminar hood for 20 minutes (RFC cabinets, AES environmental) and dissolved in 10 mL of 50
mM CaCl2 solutions together with 0.75 g GelMA to make 3.5/7.5% (w/v) Gelatin/GelMA solution. The
resulting gelatin/GelMA solution was incubated at 37°C for 16 hours or overnight with occasional stirring
to achieve a homogenous solution. For the incorporation of microspheres to the core ink, the microspheres
were added to the gelatin/GelMA solution with a concentration of 10 mg/mL and mixed with a low vortex
setting.
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3.7. Assessment of the DICAB performance using a model ink prepared from lutrol F127
A customized bioprinter, namely the Dual Ink Co-axial Bioprinter (DICAB), was employed in this study.
This bioprinter was manufactured in the Translational Research Initiative for Cell Engineering and Printing
(TRICEP) in Wollongong, Australia. Figure 10 presents the Dual Ink Co-Axial Bioprinter. It was
composed of three parts designed to move along 3D axes. The print head was designed to move along the
x-axis (1), the substrate base was designed to move along the y-axis (2), and the stepper motor was designed
to move along the z-axis (3). The print head consisted of three pieces: two independent extruders (core (4),
shell (5)), a nozzle (7), and a thermo-regulated chamber (6). The two independent extruders apply
mechanical force on the cartridges (3 mL thermo-syringes). The syringes were attached to the nozzle
through their luer lock design (7). The nozzle inlets were fabricated unevenly to ensure non-interference
when loading the syringes. The interior design of the nozzle features two gradual curved channels that
eventually form into core and shell sections, as shown in Figure 10 (8, 9). The substrate base was customdesigned to simultaneously hold small Petri dishes and cover slide glasses. The stepper motor was designed
for the print head to move along the z-axis with a precision of 0.01 mm. The control system for operating
the DICAB was based on G-code. Four experiments were performed using 30% (w/v) lutrol F-127
dissolved in PBS to validate the extrusion performance of the DICAB. The lutrol ink was dyed with 2.5%
(v/v) green and red food colorings to distinguish the core and shell.

Figure 10. Dual Ink Co-Axial Bioprinter (DICAB) manufactured in Translational Research Initiative for
Cell Engineering and Printing (TRICEP). (1) Print head. (2) Substrate base. (3) Stepper motor. (4) Core
screw and extruder. (5) Shell screw and extruder. (6) Thermo-regulated “bed”. (7) Nozzle. (8) Shell
section of the nozzle (diameter 1184 µm). (9) Core section of the nozzle (diameter 416 µm). Scale bar
500µm.
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The hardware and software communication
The communication between the hardware and software was validated with the following two experiments:
•

The communication between hardware and software that controlled the 3D movement was validated
by printing two-layer lattices with filament spacing of 2.5 mm and 1.67 mm on a cover slide. The
printing parameters were set with an extrusion rate of 0.23 µl/mm, a speed of 100 mm/min, a core/shell
ratio of 1/3, and a dimension of 1 cm x 1 cm. The data was represented in mean±standard deviation
(n=3).

•

The communication between software and hardware that controlled the extrusion was validated by
weighing the mass of printed single-layer lattices every 15 minutes for 90 minutes. The printing
parameters were set with an extrusion rate of 0.23 µl/mm, a speed of 100 mm/min, a core/shell ratio
of 1/3, and a dimension of 1 cm x 1 cm. The data was represented in mean±standard deviation (n=3).
The mass of the single-layer lattice was calculated with the following equation:
𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎 = 𝒘𝒘𝒘𝒘𝒘𝒘𝒘𝒘𝒘𝒘𝒘𝒘 𝒐𝒐𝒐𝒐 𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑 𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅 (𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑 𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑) − 𝒘𝒘𝒘𝒘𝒘𝒘𝒘𝒘𝒘𝒘𝒘𝒘 𝒐𝒐𝒐𝒐 𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑 𝒅𝒅𝒅𝒅𝒅𝒅𝒅𝒅 (𝒑𝒑𝒑𝒑𝒑𝒑 𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑)

(3)

Extrusion rate measurement of DICAB

The DICAB’s extrusion rate was measured by extruding the core/shell lutrol inks into 40 mm straight lines
on cover slides. The printing parameters were set at a core/shell ratio of 1/3 and a speed of 100 mm/min.
The extrusion rate was increased from 0.23 µL/mm to 0.38 µL/mm with 0.05 µL/mm increment on each
print. The fiber width was measured and plotted against its corresponding extrusion rate. The data was
shown in mean±standard deviation (n=3).
Core/shell extrusion rate of DICAB
The communication between the hardware and software that controlled the coaxial ratio was validated
by extruding core/shell lutrol inks with varying ratios (1:1, 1:3, 1:4, and 1:9) into the air. The printing
parameters were set at an extrusion rate of 0.23 µl/mm and a speed of 100 mm/min. The continuously
extruding coaxial fiber images were captured, and the core and the shell diameters were measured by
Image J software. The measurements were taken from three random points. The data was represented
in mean±standard deviation (n=3). The experimental (printed) core diameter was measured and
compared with the programmed core diameter. The programmed diameter of the core fiber was
calculated by the following equation assuming the extruded coaxial (core/shell) fiber was a cylinder
(solid cylinder/hollow cylinder). According to the software, the relationship of core/shell volume is
defined as:
𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓
𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽
=
𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔 𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓 𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽
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(4)

Then the volume of the core and shell are:
𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽 = 𝝅𝝅 ∗ 𝒉𝒉 ∗ (𝑹𝑹𝟐𝟐 − 𝒓𝒓𝟐𝟐 )
𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽 = 𝝅𝝅 ∗ 𝒉𝒉 ∗ 𝒓𝒓𝟐𝟐

(5)
(6)

The programmed core radius was calculated with the following equation based on the core/shell ratio
relationship with the core/shell fiber volume.
𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓
𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔
𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓
𝒓𝒓 = �
𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓
𝟏𝟏 +
𝒔𝒔𝒔𝒔𝒔𝒔𝒍𝒍𝒍𝒍 𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓
𝑹𝑹𝟐𝟐 ∗

(7)

where R represents the radius of the shell fiber, and r represents the radius of the core fiber.
Fabrication of multi-layer 3D constructs using Dual Ink Co-Axial Bioprinter (DICAB)
The fabrication of multi-layer 3D constructs using the DICAB was established by printing 2,4,8,10 and 20
layers of lattices. The printing parameters were set at an extrusion rate of 0.23 µl/mm, a speed of 100
mm/min, a core/shell ratio of 1/3, and a dimension of 1 cm x 1 cm. The images were captured by Leica
M205A (Leica Microsystems, Wetzlar, Germany) microscope, and the heights were measured by Image J
software.

3.8. The assessment of shell ink printability by the Dual Ink Co-Axial Bioprinter
(DICAB)
The shell ink printability was assessed after DICAB performance was validated with the lutrol inks. The
shell inks were prepared by adding a series of gelatin concentrations (2.5%, 3.5%, and 5% w/v) to the
2/7.5% (w/v) alginate/GelMA ink which was previously established by [33]. Two tests were performed on
DICAB by loading the shell inks to the core chamber. The first test was designed to assess the shell ink
fiber morphology. For this purpose, a continuous fiber was extruded into the air with an extrusion rate of
0.23 µl/mm, and prior to the breaking point, the fiber length was captured by a 16 MP f/1.8 aperture 75°
normal angle camera. The second test was designed to assess the shell ink extrusion deposition. For this
purpose, multi-layer (2, 4, and 6 layers) 3D constructs were fabricated with the shell ink formulation. The
printing parameters were set at an extrusion rate of 0.23 µl/mm, a speed of 100 mm/min, a dimension of 1
cm x 1 cm, and a filament spacing of 2.5 mm. The images of multi-layer 3D constructs were captured by
Leica 205A (Leica Microsystems, Germany) microscopy.

3.9. Rheological characterization of the shell ink
The rheological behavior tests were done on TA instruments AR-G2 controlled-stress rheometer equipped
with 2° 20 mm stainless steel geometry (New Castle, DE). A water trap was also equipped during each test
to reduce dehydration. The gap between the geometry plates was set at 52 µm, and approximately 750 µl
sample was loaded each time. The tests were performed three times, and the data was shown as an average
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with its corresponding standard deviation. Only a single test was performed on each sample, and the
samples were discarded afterward. Prior to experiments, the samples were warmed at 37°C for 30 minutes
then loaded into pre-warmed rheometer plates at 37°C. The loaded samples were then allowed to
equilibrate for 5 minutes. The following rheological experiments were performed on 2/3.5/7.5% (w/v)
alginate/gelatin/GelMA ink. For comparison, 2/7.5% (w/v) alginate/GelMA ink without adding gelatin
was evaluated with the same conditions.
First, the ink’s temperature dependency was measured by an oscillatory temperature sweep test. The test
was performed using a range of 5ºC to 37ºC with a ramp of 1.5ºC per minute. The storage modulus (G’)
and loss modulus (G”) was recorded as a function of temperature during the experiment. The parameters
were set at a strain of 0.1% and a frequency of 1 Hz. The sol-gel transition temperature was defined by the
intersection point of the storage and loss modulus (G’=G”). Based on the results, subsequent rheological
tests were performed at 15ºC or 22.5ºC, corresponding to an optimal gelling temperature for 2/7.5% (w/v)
alginate/GelMA ink and 2/3.5/7% (w/v) alginate/gelatin/GelMA ink, respectively.
The gelatin incorporation effect on the ink’s flow behavior was studied with time sweep (30 minutes),
strain sweep (0.1-1000%), and frequency sweep (1-100Hz) tests. The storage modulus (G’) and loss
modulus (G”) were recorded with their corresponding parameter ranges (time, strain, and frequency)
during the experiments. The rheological tests were performed at 0.1% strain and 1 Hz frequency unless
indicated otherwise.
The rotational shear viscosity test was performed on the inks to study their shear-thinning behavior. The
inks were subjected to a shear range of 0.1 s-1 to 1000 s-1, and the viscosity (Pa ˟ s) was recorded. The step
strain test was performed on the inks to study the self-recovery. The inks were subjected to 0.1% strain
stress (low) for 3 minutes and then a sudden increase of 1000% strain stress (high) for 30 seconds during
the experiment. The storage modulus (G’) was recorded as a function of time during high and low strain
stress cycles. The data was represented in mean ± standard deviation (n=3).

3.10. Viscosity characterization of the microspheres incorporated core ink
A rotational shear viscosity test evaluated the effect of the microsphere incorporation on the core ink’s
flow behavior. The microsphere incorporated core ink was subjected to a shear range from 0.1 s-1 to 1000
s-1, and the viscosity (Pa ˟ s) was recorded. The microsphere incorporated core ink was prepared by adding
10 mg/mL microspheres to the core ink. The test was performed at 22.5°C, 1 Hz of frequency, and 0.1%
strain stress. For comparison, core ink without microspheres was evaluated with the same parameters. The
data was represented in mean±standard deviation (n=3).

3.11. Fabrication of 3D constructs
The shell ink composed of 2/3.5/7.5% (w/v) alginate/gelatin/GelMA and the core ink composed of
3.5/7.5% (w/v) gelatin/GelMA were prepared as described in section 3.6. Prior to printing, Lithium phenyl29

2,4,6-trimethyl-benzoyl phosphinate (LAP) was added to the core and shell inks at a final concentration of
0.06% (w/v). The printing parameters were set at an extrusion rate of 0.33 µl/mm, a speed of 100 mm/min,
and a core/shell ratio of 1:3. Immediately after printing, the four-layer 3D scaffolds were photo-crosslinked
using Omnicure LX505 (400 nm light source) at a photo-energy of 562 mJ for 1 minute on each side, then
further crosslinked in 2% CaCl2 solution for 20 minutes. The dimension of the 3D constructs was 1 cm x
1 cm in length, 3.5±0.04 mm in height, with filament spacing of 1.67 mm. The average weight of the 3D
constructs was 379±2.6 mg. Prior to the experiment, the bioprinter and all consumables were sterilized
with 70% ethanol then under UV light (RFC cabinets, AES environmental) for 20 minutes, and the printing
process was performed in the laminar hood (RFC cabinets, AES environmental).
Verification of the coaxial resolution by confocal imaging
Two types of single-layer coaxial lattices were fabricated with printing parameters set at an extrusion rate of
0.23 µl/mm, a speed of 100 mm/min, and a filament spacing of 2.5 mm. The first type of single layer coaxial
lattice was composed of rhodamine B labeled 3.5/7.5% (w/v) gelatin/GelMA in 50mM CaCl2 as the core
ink, and FITC labeled 2/3.5/7.5% (w/v) alginate/gelatin/GelMA as the shell ink. The second type of single
layer coaxial lattice was composed of rhodamine B labeled 2/3.5/7.5% (w/v) alginate/gelatin/GelMA as the
core ink, and FITC labeled 2/3.5/7.5% (w/v) alginate/gelatin/GelMA as the shell ink. The fluorescently
labeled GelMA-FITC and GelMA-rhodamine B were incorporated into the core/shell inks with a 0.375%
(w/v) concentration. Coaxial resolution images of the two samples were acquired using a confocal laser
scanning microscope (CLSM, Leica TSC SP5 II).

3.12. Characterization of the coaxially printed 3D constructs
Mechanical properties of the 3D coaxial constructs
The 3D constructs were placed into 12 well-plates filled with incubating media. The incubating media was
composed of Dulbecco’s Modified Eagle Medium (DMEM) with 1% (w/v) pen-strep and 0.05% (w/v)
sodium azide. Three 3D constructs were subjected to compression testing each week for four weeks. The
compression tests were performed at room temperature using an EZ-S mechanical tester (Shimadzu, Japan)
fitted with a 10 N load cell. The samples were first removed from the media and compressed between two
stainless plates where the upper plate displacement was controlled by a constant rate of 0.5 mm/min. The
compression test was continued until the ultimate compression strength was reached, right before the
disintegration of the samples. The young’s modulus or the elastic modulus of the scaffold was calculated
from a 10-15% strain range. The data was shown in mean±standard deviation (n=3).
Water uptake study of the 3D coaxial constructs
The coaxial 3D constructs were soaked in DI water for 24 hours to remove any free polymers. The washed
scaffolds were then frozen and lyophilized overnight. The lyophilized scaffolds were first weighed (Wi)
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then soaked in DI water. The swollen hydrogels (Ws) mass was weighed within 1 hour, 3 hours, 24 hours,
and 48 hours. Before the measurements, excess water of the swollen hydrogels was removed gently by
dabbing kim wipe on the surface. The following equations calculated the water uptake, and the data was
represented in mean±standard deviation (n=3).

𝑾𝑾𝑾𝑾𝑾𝑾𝑾𝑾𝑾𝑾 𝒖𝒖𝒖𝒖𝒖𝒖𝒖𝒖𝒖𝒖𝒆𝒆 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 (%) =

𝑾𝑾𝑾𝑾 − 𝑾𝑾𝑾𝑾
∗ 𝟏𝟏𝟏𝟏𝟏𝟏
𝑾𝑾𝑾𝑾

(8)

3.13. Incorporation of VEGF-A165 laden PLGA microspheres to the 3D constructs
In vitro release study of VEGF-A165 from the coaxial 3D constructs
Two types of 3D constructs were fabricated as described in section 3.11. The first type of 3D construct
contained VEGF-A165 incorporated microspheres in the core. The VEGF-A165 microspheres were
incorporated into the core ink with a 10 mg/mL concentration prior to the fabrication process. The second
type of 3D construct contained VEGF-A165 in the core. The VEGF-A165 was directly incorporated into
the core ink with a 1 µg/mL concentration prior to the fabrication process. The 3D constructs were first
photo-crosslinked and then physically crosslinked right after printing. Each twice crosslinked scaffold was
placed into a trans-well filled with 4 mL release media. The release media was composed of basal DMEM
with 1% (w/v) pen-strip, 1% BSA (w/v), and 0.05% (w/v) sodium azide. On days 1, 3, 7, 10, 14, 18, 21,
24, and 28, 1 mL of release media was pipetted from each transwell into an effendorf tube, and the
remaining release media was discarded afterward. The empty transwell was then replenished with new 4
mL release media on every time-point. ELISA measured the released VEGF-A165 from the 3D constructs
according to the manufacturer’s protocol. Briefly, 100 µl of released VEGF-A165 was pipetted into capture
antibody-coated 96-well plates in duplicates and incubated at room temperature. After 2 hours, the wells
were washed three times with 200 µl of wash buffer, then 100 µl of detection antibody was pipetted into
each well and incubated at room temperature. After 2 hours, the wells were washed three times with 200
µl of wash buffer, then 100 µl of working dilution of streptavidin-HPR was pipetted into each well and
incubated further at room temperature. After 20 minutes, the wells were washed three times with 200 µl
of wash buffer, then 100 µl of substrate solution was pipetted into each well and further incubated for 20
minutes at room temperature. The reaction was terminated by adding 50 µl of stop solution, and the optical
density of the wells read at 450 nm (Bio-Rad Model 680). The net VEGF-A165 release was first calculated
according to the standard curve equation created from each experiment. The data was represented in
mean±standard deviation (n=3).
3.13.1.1. Calculation of the incorporated VEGF-A165 within the 3D constructs
The incorporated VEGF-A165 amount was calculated from the core ink spent fabricating the 3D construct.
The average weight of the 3D constructs was 379±2.6 mg when fabricated with an extrusion rate of 0.33
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µl/mm, a speed of 100 mm/min, a core/shell ratio of 1/3, a filament spacing of 1.67 mm, and a dimension
of 1 cm x 1 cm. The average weight was calculated by weighing twelve 3D constructs right after the photocrosslinking process. The density of the core/shell (coaxial) ink with a ratio of 1/3 was measured by
weighing 1 mL coaxial ink (250 µl core ink mixed with 750 µl of shell ink). The mass of the 1 mL core
and shell inks mixed with a ratio of 1:3 measured 1±0.03 g. Based on the density of the core/shell inks, the
total volume of 379±2.6 µL coaxial ink was used for fabricating 3D constructs, and the volume of the core
ink was calculated with the following equation:

𝑽𝑽𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒊𝒊𝒊𝒊𝒊𝒊 =

𝑽𝑽𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒊𝒊𝒊𝒊𝒊𝒊
∗ 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓
𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓 + 𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔 𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓

(9)

The amount of microsphere incorporated into the core ink was calculated by the following equation:
𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎 = 𝑽𝑽𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒊𝒊𝒊𝒊𝒊𝒊 ∗ 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎

(10)

The amount of VEGF-A165 incorporated into the core ink was calculated by the following equation:
𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽−𝑨𝑨 = 𝑽𝑽𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒊𝒊𝒊𝒊𝒊𝒊 ∗ 𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽−𝑨𝑨
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(11)

4. Result and Discussion
The bioink formulation is one of the defining factors for achieving a successful biofabrication
application. Ideally, a bioink should possess suitable mechanical strength and excellent biocompatibility
with the targeted tissue to be replaced. The biomaterials frequently used for the scaffold fabrication of
insulin-producing cells are alginate, collagen, and gelatin [21]. Prior to this study, the previously
established bioink [33] was based on alginate and GelMA, which showed good printability at 15ºC. The
preliminary study showed high cell viability and proliferation over three weeks when mouse pancreatic
endothelial cells (MS1) were incorporated with the alginate/GelMA bioink [33]. As the next step for bioink
formulation, this study focused on further improving the bioinks printability at room temperature and
increasing structural stability and resolution of the 3D constructs. In addition, controlled growth factor
incorporation to the printed constructs was also explored to increase the biological property of the
scaffolds.

4.1. Synthesis of gelatin methacryloyl (GelMA)
The GelMA is a photo-cross linkable hydrogel derived from gelatin [35]. Figure 11A presents the GelMA
synthesis where gelatin reacted with methacrylic anhydrate and amine/hydroxyl groups of amino acid
residues substituted with methacryloyl [35]. Depending on the degree of modification, the physical
properties such as compressive modulus of the GelMA vary [35]. The degree of modification of GelMA
prepared in this project was determined by a ninhydrin assay.

Figure 11. (A) Synthesis of GelMA. (I) gelatin, (II) methacrylic anhydride, (III) gelatin methacryloyl.
Adapted from [35]. (B) Schematic diagram of ninhydrin reaction with amino acids. (IV) ninhydrin
molecule, (V) amino acids, (VII) Ruhemann's purple (diketohydrindylideneddiketohydrindamine) Adapted
from [36].
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In this colorimetric assay, the amine groups of amino acid reacted with ninhydrin molecule (2,2dihydroxyindane-1,3-dione) to create the chromophore known as Ruhemann’s purple (570 nm), shown in
Figure 11B [36]. The degree of modification was calculated from the absorbance difference between the
reacted amine group of modified (GelMA) and unmodified gelatin. The Ruhemann’s purple produced from
various concentrations of unmodified gelation solutions were shown in Figure 12B. The highest
concentrated gelatin solution (40 mg/mL) showed an absorbance of 0.7, while the lowest concentrated
gelatin solution (2.5 mg/mL) showed 0.1 at 570 nm. The regression line drawn from the gelatin
concentrations showed R2 = 0.9973. The regression line produced from the known gelatin concentrations
was used as a standard curve, shown in Figure 12A. The absorbance of GelMA samples (40 mg/mL)
measured 0.23±0.001, and the observed concentration of GelMA was calculated to be 7.17±0.1 mg/mL
from the regression line. The Degree of Modification (DoM) was calculated at 82±0.24% based on the
observed GelMA concentration. This calculation suggested that 82% of the amine groups of the gelatin
was substituted with methacryloyl groups during GelMA synthesis.

Figure 12. Ninhydrin assay to determine the Degree of Modification (DoM) of the GelMA prepared in this study.
(A) Gelatin standard solution was created by drawing regression line between series of gelatin concentrations
and their corresponding absorbances. The data points represented in mean±sd (n=3). (B) The visual
representation of the gelatin standard solutions (40, 20, 10, 5, 2.5, and 0 mg/mL) and GelMA samples (40
mg/mL) after treated with ninhydrin.

4.2. Fabrication of VEGF-A165 incorporated microspheres
PLGA microspheres were prepared for this project as a delivery system for VEGF-A165. Compared to
other growth factors, the VEGF-A165 is reported to play important roles not only for the development and
maturation of islets but also for mature islets to maintain their vascular structure [37]. Brissova et al. (2006)
demonstrated that all islet cell types, including alpha and beta cells, express VEGF-A165 [37]. However,
regulating the VEGF-A165 dose is difficult. For example, Cai et al. (2012) showed that prolonged
overexpression of VEGF-A165 results in an increasing number of endothelial cells and a decreasing
number of the beta-cell area causing morphogenic abnormality and glucose intolerance in mice [38].
Interestingly, brief overdose did not affect the beta cells as much as the prolonged overexpression [38]. In
contrast, knock-out or decreased VEGF-A165 expression in islet cells negatively impacts glucose tolerance
and vessel density [39]. This decreased expression indicates that tight control of VEGF-A165 is required
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in order to enable revascularization. The VEGF-A165 concentration range used for 3D angiogenesis
studies was reported between 25-100 ng/mL [28-31]. The water-in-oil-in-water (w1-o-w2) emulsion
method was employed to prepare VEGF-A165 laden PLGA microspheres for the controlled delivery of
VEGF-A165. Briefly, the inner water phase (w1) contained the growth factor emulsified with organic
phase (o), where the organic phase contained the PLGA polymer. This process created the first emulsion
of water-in-oil (w1-o). Then the first emulsion was emulsified again with the outer water phase to create
water-in-oil-in-water (w1-o-w2) microspheres. As the fabrication parameters influence the release profile
as well as microsphere morphology and size, three fabrication parameters were investigated, including
compositions of inner aqueous phase (w1), polymer concentration of oil phase (o), and volume of outer
water phase (w2).
Inner water composition effect on the microsphere particle size and VEGF-A165 release
profile
First, the VEGF-A165 stock solution was prepared by dissolving 10 µg VEGF-A165 in 100 µl of 1% BSA
in PBS. The microspheres were fabricated with two protocols to evaluate the effect of the inner water phase
(w1) on the microsphere size, morphology, and release profile. In the first protocol, the inner water phase
was prepared by adding 90 µl deionized water to the 10 µl VEGF-A165 stock solution, resulting in 0.1%
(w/v) BSA|PBS in the solution. In the second protocol, the inner water phase was prepared by adding 90
µl 1% (w/v) BSA|PBS to the 10 µl VEGF-A165 stock solution, resulting in 1% (w/v) BSA|PBS in the
solution.
Table 2. Evaluated inner water components.

Protocol-1

Components of the inner water phase (100µL)
VEGF-A165 stock (100
BSA solution (10 mg/mL)
PBS buffer (10 mg/mL)
µg/mL)
0.001% (w/v)
0.1% (w/v)
0.1% (w/v)

Protocol-2

0.001% (w/v)

1% (w/v)

1% (w/v)

Figures 13A and 13C present the microsphere morphology and the particle size distribution fabricated with
protocol-1. The average microsphere diameter fabricated with protocol-1 measured 30±11 µm, and about
98% of the microspheres had a diameter between 20-60 µm. Figures 13B and 13D present the microsphere
morphology and size distribution fabricated with protocol-2. The average microsphere diameter fabricated
with protocol-2 measured 46±23 µm, and about 82% of the microspheres had a diameter between 20-60
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µm. Figure 13E presents the in vitro VEGF-A165 release from the microspheres fabricated with protocol1 and protocol-2. The VEGF-A165 release from the microspheres fabricated by protocol-1 measured 0.31
ng/mg on day one, 0.67 ng/mg on day ten, and 0.7 ng/mg on day twenty-eight. In contrast, the VEGFA165 release from the microspheres fabricated by protocol-2 measured 0.37 ng/mg on day one, 1.06 ng/mg
on day ten, and 1.14 ng/mg on day twenty-eight.

Figure 13. Effect of the inner water phase composition on the microsphere morphology, size distribution,
and VEGF-A165 release profile. (A) Morphology of microspheres fabricated with inner water composition
of 0.1% (w/v) BSA|PBS (protocol-1) and (C) their particle size distribution. (B) Morphology of
microspheres fabricated with inner water composition of 1% (w/v) BSA|PBS (protocol-2) and (D) their
particle size distribution. Scale bar 100 µm. (E) In vitro VEGF-A165 release behavior from the
microspheres fabricated with protocol-1 (presented by red line) and protocol-2 (presented by black line).
The data points represented in mean±sd (n=3).

The microspheres fabricated by protocol-2 had ten times higher BSA protein and salt concentration than
protocol-1. The higher salt and BSA content increased the cumulative VEGF-A165 release by 1.2 times
on the first day and 1.6 times on day ten. However, after day ten, VEGF-A165 release dropped
significantly, and there was no difference between microspheres fabricated by protocol-1 and protocol-2.
The results suggested that the VEGF-A165 release behavior and microsphere size were influenced by the
inner water components (salt concentration and BSA concentration). The release behavior could be
influenced either solely or in a combination of the inner water components. A study examining the
influence of BSA protein by Yang et al. (2001) reported that the increase of BSA concentration resulted
an increase in burst release [40].
Furthermore, they did not find significant size variation between microspheres fabricated with 4.8%, 1.1%,
and 0.57% BSA concentration [40]. Another study examining the influence of PBS salt by [41] reported
that salt concentration increased the burst release and the particle size. They explained that increased
particle size was due to a higher osmotic gradient caused by an increased PBS concentration in the inner
water phase. The high osmotic gradient of the internal water phase attracted the outer water phase during
the second emulsion process, thus creating bigger internal water droplets. As a result, the microspheres
with increased particle size and more porous internal structure were fabricated [41].
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PLGA polymer concentration effect on the microsphere particle size and VEGF-A165 release
profile
The polymer concentration effect on the microsphere size, morphology, and VEGF-A165 release profile
was evaluated by two PLGA concentrations (10% and 15% (w/v)). Figure 14A presents the resulting
microsphere morphology fabricated with 10% (w/v) polymer concentration. The average diameter of the
microspheres measured about 30±11 µm, and about 98% of the microspheres had a diameter between 2060 µm (Figure 14C). Figure 14B presents the resulting microsphere morphology fabricated with 15% (w/v)
polymer concentration. Microspheres with diameters of more than 100 µm were also fabricated during the
fabrication process (Figure 14B (indicated with red arrows)). The average diameter of the microspheres
measured about 38±17.3 µm. About 86% of the measured microspheres had a diameter between 20-60 µm
(Figure 14D), and about 7% of the measured microspheres had an average diameter of 186±62 µm. The
increase of polymer concentration contributed to the higher polymer entanglement during the emulsion
process, thus increasing the microsphere size. This result was also observed in a study conducted by Yang
et al. (2001) [40].

Figure 14. Evaluation of the effect of 10% and 15% (w/v) PLGA on the microsphere morphology, size
distribution, and VEGF-A165 release profile. (A) Morphology of microsphere fabricated with 10% (w/v)
PLGA and (C) their particle size distribution. (B) Morphology of microspheres fabricated with 15%
(w/v) PLGA and (D) their particle size distribution. Red arrow presents the microspheres with diameter
larger than 100 µm. Scale bar 100 µm. (E) In vitro VEGF-A165 release behavior of microspheres
fabricated with 15% (w/v) (presented by red line) and 10% (w/v) PLGA (presented by black line) for a
period of four weeks. The data points represented in mean±sd (n=3).

The in vitro release of the VEGF-A165 over four weeks showed no difference between microspheres
fabricated with 10% and 15% (w/v) PLGA concentrations (Figure 14E).
Outer water (w2) volume effect on the microsphere particle size and VEGF-A165 release
profile
Two protocols were tested to evaluate the outer water phase effect on the VEGF-A165 release profile and
microsphere size. The first protocol was prepared as an organic/outer water phase (o/w2) ratio of 1/2,
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referred to as the low volume. The second protocol was prepared as organic/outer water phase (o/w2) of
1/10, referred to as the high volume. Figure 15A and 15B presents the microsphere morphology and the
particle size distribution of microspheres fabricated with the low volume. The average diameter of the
microspheres measured about 88±70 µm, and about 72% of the microspheres had a diameter between 2060 µm. In addition, about 20% of the microspheres had a diameter of more than 100 µm. Figures 15C and
15D present the morphology and size distribution of the microspheres fabricated with the high volume
outer water phase. The average diameter of the microspheres measured about 40±26 µm, and about 86%
of the microspheres had a diameter between 20-60 µm. The average diameter between the microspheres
fabricated with high (40±26 µm) and low volume (88±70 µm) of outer water phase indicated the high
volume outer water phase resulted in smaller microspheres. This result was consistent with a study reported
by Parikh et al. (2002) that showed decreased particle sizes with an increasing volume of outer water phase
[42]. They explained that an increased amount of outer water phase gave less chance for the first emulsion
to collide during the second emulsion process, which caused a decrease in particle size [42].

Figure 15. Outer water volume effect on the microsphere morphology, size distribution, and VEGF-A165
release profile. (A) The morphology of microspheres fabricated with o/w2 ratio of 1/2 and its (B) size
distribution. (C) The morphology of microspheres fabricated with o/w2 ratio of 1/10 and its (D) size
distribution. Scale bar 100 µm. (E) In vitro VEGF-A165 release behavior from the microspheres fabricated
with o/w2 ratio of 1/10 (presented by red line) and o/w2 ratio of 1/2 (presented by black line) for a period of
four weeks. The data points represented in mean±sd (n=3).

Figure 15E presents in vitro VEGF-A165 release from the microspheres fabricated with o/w2 ratios of 1/2
(lower volume of outer water phase) and 1/10 (higher volume of outer water phase). The VEGF-A165
release from microspheres fabricated with the low volume measured 0.37 ng/mg on day one and 1.06
ng/mg on day ten. In contrast, VEGF-A165 release from microsphere fabricated the high volume measured
0.72 ng/mg on day one and 1.8 ng/mg on day ten. Similar to other experiments, the VEGF-A165 release
was dropped significantly after day ten from the microspheres fabricated with the high and low volume of
outer water phase. The microspheres fabricated with the high volume of outer water phase increased the
VEGF-A165 release by 1.9 times on day one and 1.7 times on day ten compared to microspheres fabricated
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with the low volume of the outer water phase. Similar release behavior was also observed by Lin et al.
(2018), where the release from the small microspheres was more rapid than the big microspheres [43].
Effect of the growth factor concentration on the release profile
Based on the three experiments performed above, the following parameters were selected for the
microsphere fabrication: 0.001% (w/v) VEGF-A165 and 1% (w/v) BSA and PBS as inner water phase,
10% (w/v) PLGA, and organic phase (o) /outer water phase (w2) ratio of 1/10. The VEGF-A165
concentration used for 3D angiogenesis studies was reported between 25-100 ng/mL [28-31]. The VEGFA165 loading used for evaluating fabrication parameters was 10 ng/mg, which did not produce a sufficient
release. In order to reach the appropriate VEGF-A165 release amount, the VEGF-A165 loading was
increased from 10 ng/mg to 100 ng/mg. The increase of VEGF-A165 concentration was evaluated by
comparing the VEGF-A165 release behavior of low (10 ng/mg) and high (100 ng/mg) VEGF-A165
loadings over four weeks (Figure 16).

Figure 16. The VEGF-A165 release behavior from the microspheres fabricated with the low VEGFA165 loading compared to the high VEGF-A165 loading. Red line presents the VEGF-A165 release
from the microspheres fabricated with 10 ng/mg VEGF-A165 loading. Black line presents the VEGFA165 release from the microspheres fabricated with 100 ng/mg loading. The VEGF-A165 burst release
increased from 0.72 ng/mg to 20.3 ng/mg on the first day. However, the general release behavior did
not change. The data points represented in mean±sd (n=3).

Higher VEGF-A165 loading increased the burst release from 0.72 ng/mg to 20.3 ng/mg on the first day.
The following days the VEGF-A165 release from the microspheres fabricated with 100 ng/mg VEGFA165 loading measured 22.2 ng/mg on day ten and 22.45 ng/mg on day twenty-eight. In contrast, the
VEGF-A165 release from the microspheres fabricated with 10 ng/mg VEGF-A165 loading measured 1.8
ng/mg on day ten and 1.9 ng/mg on day twenty-eight. This result suggested that the general trend of the
release pattern remained consistent between the 10 ng/mg and 100 ng/mg VEGF-A165 loadings, and the
increase of VEGF-A165 loading only affected the burst release.
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The microspheres lost about 57% of their mass and retained their spherical structure on day twenty-eight
during the in vitro study. Figure 17 presents the morphological change of the PLGA (MW: ~22kDa)
microspheres before and after in vitro study. These findings were not consistent with the study conducted
by Karal-Yilmaz et al. (2011), where they reported that on day fourteen, PLGA (MW: ~26kDa)
microspheres lost 8% of their mass, and on day thirty-five, the microspheres lost 92% of their mass [44].
They also reported that the microspheres started losing their structure by day twenty-one and completely
lost the spherical structure by day thirty [44]. A possible explanation for the slower degradation of the
PLGA microspheres in this study could be associated with the degradation environment. When PLGA
microspheres degrade into their monomers (lactic and glycolic acid), it changes the pH of the release buffer
from neutral to acidic, which autocatalyzes the degradation process [45]. However, the frequent
replacement of release buffer (1% (w/v) BSA in PBS) during the release study could have reversed the pH
from acidic to neutral, which slowed down the PLGA microsphere degradation in this study.

Figure 17. VEGF-A165 incorporated PLGA microspheres morphology change
during in vitro VEGF-A165 release study. (A) The morphology of the microspheres
prior to release experiment (B) The morphology of the microspheres following 28
days in vitro release in 1% BSA in PBS. The data points represented in mean±sd
(n=3). Scale bar 100 µm.

4.3. Printability assessment of Dual-Ink Co-axial Bioprinter (DICAB) by Lutrol F-127
The Translational Research Initiative Cellular Engineering and Printing (TRICEP) facility developed the
Customized Dual Ink Co-axial Bioprinter (DICAB). It is equipped with two separate bioink chambers
capable of printing coaxial fibers through the coaxial nozzle. The inner diameter of the nozzle measured
416 µm, and the outer diameter of the nozzle measured 1184 µm. The DICAB’s extrusion performance
was validated by four experiments using lutrol polymer. Lutrol® F-127 is a poly (ethylene glycol)-blockpoly (propylene glycol)-block-poly (ethylene glycol) polymer with an average molecular weight of 13kDa.
Solutions containing this material are commonly used for testing printability of the bioprinters, and a 30%
(w/v) lutrol solution was used in this study. The gelling temperature for 27% (w/v) lutrol was reported
below 15ºC [46].
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Figure 18. Verification of 3 axes (X, Y, Z) movement of the DICAB. (A1) First input of a two-layer
lattice with a dimension of 1 cm x 1 cm and a filament spacing of 2.5 mm. (B1) presents its
corresponding output (printed structure). (A2) Second input of a two-layer lattice with a dimension of 1
cm x 1 cm and a filament spacing of 1.67 mm. (B2) presents its corresponding output (printed
structure). Scale bar 0.5 mm.

Evaluation of the hardware and the software communication
Two experiments were undertaken to assess the printer’s hardware and software communication. The first
experiment aimed to assess the communication of the software and hardware that controls the movement
of the 3 axes (X, Y, Z). The experiment was done by giving the software two design inputs and validating
if the output reflected the input value, shown in Figure 18.
The printing parameters were set at an extrusion rate of 0.23 µl/mm, a speed of 100 mm/min, and a
core/shell ratio of 1/3. The first input was set to print a two-layer lattice with a dimension of 1 cm x 1 cm
and a filament spacing of 2.5 mm (Figure 18A1). The printed lattice’s dimension measured 10.9±0.3 mm,
and the filament spacing measured 3.0±0.3 mm (Figure 18B1). The second input was set to print a twolayer lattice with a dimension of 1 cm x 1 cm and a filament spacing of 1.67 mm (Figure 18A2). The
printed lattice’s dimension measured 1.06±0.6 mm, and the filament spacing measured 1.2±0.2 mm (Figure
18B2).

Figure 19. Verification of extrusion consistency of the DICAB. The extrusion consistency was tested
by measuring the weight of a single layer lattice printed with an extrusion rate of 0.23 µl/mm, a speed
of 100 mm/min, a core/shell ratio of 1/3 and a filament spacing of 2.5 mm. The data points
represented in mean±sd (n=3).
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Next, the extrusion consistency of the bioprinter was assessed. A single layer of the coaxial lattice was
printed with an extrusion rate of 0.23 µl/mm, a speed of 100 mm/min, and a core/shell ratio of 1/3. The
dimension was set to 1 cm x 1 cm with a filament spacing of 2.5 mm. The three lattices were printed every
15 minutes for 90 minutes, and the weight of each printed lattice was measured at each time point. Figure
19 presents the verification of extrusion consistency. The average lattice weight printed at each time-point
was 57±1.7 mg, and there was no significant variation of inconsistent extrusion with time. These two
experiments demonstrated DICAB’s consistent ink deposition, reliable mechanical movement, and wellestablished communication between the hardware and software.
Extrusion rate measurement of Dual Ink Co-Axial Bioprinter (DICAB)
One of the critical factors for the printed structure is shape fidelity. As the extrusion rate influences shape
fidelity, it plays a significant role in creating the microchannels within the scaffold, facilitating cell survival
by the oxygen and nutrient transfer. If the ink extrusion rate is too high, the neighboring extruded filaments
can merge, leaving no pores and impeding the nutrient transfer in the case of cell-laden structures. The
programmed extrusion rate of DICAB was calculated by the mechanical force generated by the stepper
motor. The 40 mm long filaments were printed by varying extrusion rates. The diameter of the filaments
was measured by the ImageJ software program. The printing parameters were set with a 100 mm/min
speed and a core/shell ratio of 1/3 (with the same colored lutrol ink). Figure 20A presents the visual
representation of the filaments extruded with increasing extrusion rates. The increased extrusion rate
caused an increased flow of extruded material from the bioprinter, shown in figure 20B.

Figure 20. Extrusion rate evaluation of the coaxial bioprinter with the lutrol ink. (A) A visual representation of
width produced by single ink coaxial fibers at various extrusion rates. Scale bar 1 mm. (B) The measured fiber
width with corresponding extrusion rate value. The data points represented in mean±sd (n=3).

Core/shell extrusion ratio of DICAB
The core/shell ratio, also referred to as the coaxial ratio, was defined as the ratio between the movements
of the core screw compared to the movement of the shell screw, both of which were controlled by
individual stepper motors. This experiment investigated the relationship between the programmed and
42

the experimental core/shell ratios. Continuous fibers were extruded into the air with an extrusion rate
of 0.23 µl/mm with programmed ratios of core/shell during the experiment. The diameter of the
experimental (printed) core and shell were measured and compared with the programmed core diameter.
According to the software, the relationship of core/shell volume is defined as:
𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓
𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽
=
𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔 𝒓𝒓𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂 𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽

(4)

Assuming the fiber was cylindrical, the shell fiber was calculated as a hollow cylinder, and the core fiber
was calculated as a solid cylinder, respectively.
𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽 = 𝝅𝝅 ∗ 𝒉𝒉 ∗ (𝑹𝑹𝟐𝟐 − 𝒓𝒓𝟐𝟐 )

(5)
(6)

𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽𝑽 = 𝝅𝝅 ∗ 𝒉𝒉 ∗ 𝒓𝒓𝟐𝟐

where R was shell radius and r was core radius.

The programmed core radius was calculated with the following equation based on the core/shell ratio
relationship with the core/shell fiber volume.

𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓
𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔
𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓
𝒓𝒓 = �
𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓
𝟏𝟏 +
𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔𝒔 𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓
𝑹𝑹𝟐𝟐 ∗

(7)

Figure 21A presents the continuous coaxial fiber extrusion with different core/shell ratios. The
experimental diameter of the core was measured from the fiber and compared with the programmed
diameter (𝑑𝑑 = 2 ∗ 𝑟𝑟) of the core fiber. Figure 21B presents the relationship between the programmed

and experimental core diameters. The proximity of the programmed and experimental values showed a
consistent core/shell extrusion ratio.
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Figure 21. Core and shell extrusion ratio measurements. (A) The continuous coaxial fibers
extruded with different core:shell extrusion ratios (1:1, 1:3, 1:4, 1:9) using lutrol inks. Scale bar
2 mm. (B) The measured core diameters compared with their programmed diameters. The data
points represented in mean±sd (n=3).

DICAB’s ability to print multi-layer 3D constructs using lutrol inks
Another critical aspect of extrusion bioprinting is the height deposition consistency of the printed
structures. As the height of the 3D construct increases, the base layers will experience an increased load
of material which causes a decrease in the expected height of the multi-layer structure [47]. The decreased
height due to an increased weight could cause the extrusion of material to hover over the constructs during
the printing process as the layers increase. To resolve this issue, the DICAB implemented a height
adjustment function for the next layer by multiplying the current height value by an input number between
0-1. In other words, if the current height was 6 mm and the height adjustment function input value was set
to 0.9, the bioprinter would begin printing the next layer by lifting up the nozzle 5.4 mm (6 mm ∗ 0.9), not

6 mm. The multiple-layer (2, 4, 8, 10, and 20 layers) lattices were printed with coaxial lutrol-F127 inks to
evaluate the stepper motor consistency. The printing parameters were set at an extrusion rate of 0.23
µl/mm, a speed of 100 mm/min, a core/shell ratio of 1/3, and a filament spacing of 2.5 mm (Figure 22A).
The height value was set at 0.6 mm, and the height adjustment was set to 0.9. The measured 3D construct’s
height was compared against the expected height of the 3D constructs (Figure 22B). The expected height
was calculated without the height adjustment. The relationship between the height of the printed lattice
and the number of layers demonstrated the bioprinter’s consistent and uniform deposition of lutrol F-127
inks along the Z direction.
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Figure 22. The multi-layer of 3D constructs fabricated with the coaxial lutrol F-127 inks using the
DICAB. The 3D constructs were printed with an extrusion rate of 100 µl/mm, a speed of 100 mm/min
and a core/shell ratio of 1/3. Height was set to 0.6 mm and the height adjustment was set to 0.9. (A)
presents multi-layer (2,4,8,10, and 20 layers) 3D constructs. Scale bar 5 mm. (B) presents the
measured height of the 3D constructs plotted against the expected height of the 3D constructs.

4.4. Optimization of the shell ink for coaxial bioprinting
The project herein presented was a part of ongoing research on developing a 3D bioprinting platform for
implantable islet-containing constructs. Previous team members have established an ink containing 2%
(w/v) alginate and 7.5% (w/v) GelMA, namely 2/7.5% (w/v) alginate/GelMA, as both the core and shell
inks [32, 33]. 3D macroporous cell-laden constructs fabricated with this ink as the shell and core showed
retained cell viability when incorporated with endothelial progenitor cells (EPC) and islet cells [33]. The
alginate/GelMA ink was also tested to encapsulate T-regulatory cells where the cells remained viable,
functional, and phenotypically stable [32]. Built on the previous works, alginate/GelMA ink was selected
as the shell ink with a minor modification of gelatin incorporation to improve printability at room
temperature. When printing with cells, room temperature printable ink could reduce ink preparation time
and environmental stress.
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Optimization of gelatin loading to improve the printability of the shell ink at room
temperature
Gelatin, the precursor to GelMA, is a thermo-responsive polymer that forms a physical gel at a lower
temperature due to the coil to helix transition [48]. This thermo-responsive behavior is attractive to bioink
formulations. Gelatin had been explored as an ink modifier to improve the printability of bioink [32, 49].
For example, Yin et al. (2018) demonstrated that the 3D constructs fabricated using 5/8% (w/v)
GelMA/gelatin bioink had similar structural resolution as the 3D constructs printed with 30% (w/v) GelMA
bioink. Furthermore, there was no significant cell viability difference between the 3D constructs printed
with 5/8% (w/v) GelMA/gelatin bioink and 5% GelMA bioink [49].

Figure 23. Evaluation of extrudability of gelatin (2.5, 3.5, and 5% w/v) incorporated 2/7.5% (w/v)
alginate/GelMA inks using Dual Ink Co-Axial Bioprinter at room temperature. (A) The increase of gelatin
concentration effect on the filament formation. (B) The increase of incorporated gelatin concentration effect
on multi-layer (2, 4 and 6) 3D structures. The 3D constructs were fabricated from the core outlet with an
extrusion rate of 0.23 µl/mm and a speed of 100 mm/min, a dimension of 1 cm x 1 cm and a filament spacing
of 2.5 mm. Scale bar 5 mm.

The gelatin was incorporated with various concentrations (2.5%, 3.5%, and 5% w/v) to the 2/7.5% (w/v)
to the alginate/GelMA ink to increase the printability at room temperature. The effect of gelatin
incorporation was evaluated with two screening tests using the bioprinter. The first screening test assessed
how the gelatin incorporation with various concentrations affected the filament morphology at room
temperature. The test was performed by loading the gelatin incorporated alginate/GelMA inks to the core
nozzle and extruded fibers into the air (Figure 23A). At the nozzle outlet, the 2/7.5% (w/v) alginate/GelMA
ink formed droplets, indicating the ink was liquid at room temperature and therefore deemed unprintable.
The 2/7.5% (w/v) alginate/GelMA inks with gelatin incorporation of 2.5%, 3.5% or 5% (w/v) all formed
filaments. This result suggested gelatin incorporated alginate/GelMA inks were in an extrudable gel state
at room temperature. The 5% (w/v) gelatin incorporated 2/7.5% (w/v) alginate/GelMA ink showed the
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longest continuous filament while the blends with 2.5% and 3.5% (w/v) gelatin concentrations formed
continuous filaments less than 3 cm and 3.5 cm, respectively. The second test was performed to evaluate
the shape fidelity of multiple-layer structures. The 3D constructs were printed from the core outlet with an
extrusion rate of 0.23 µl/mm, a speed of 100 mm/min, and a filament spacing of 2.5 mm. Figure 23B
presents the 3D constructs printed with various concentrations of gelatin incorporated inks. The 2.5% (w/v)
gelatin incorporated alginate/GelMA ink showed filament spread during the printing process. The filament
spread was further enhanced with the increasing lattice layers, where some of them were merged (Figure
23B). This filament spread indicated that the 2.5% (w/v) gelatin incorporated ink lacked shape fidelity.
On the other hand, 3.5% and 5% (w/v) gelatin incorporated alginate/GelMA inks retained fiber structure
during printing and 3D printed structures. However, the 5% (w/v) gelatin incorporated ink produced nonuniform and rougher filaments than those filaments printed with 3.5% (w/v) gelatin incorporated ink. The
non-uniform and rough morphology became more apparent as the layers of 3D constructs increased. An
over-gelled ink is not typically favored in extrusion-based bioprinting due to non-uniform fiber deposition
that could lead to undesirable scaffold morphology and stability [47]. The 3.5% (w/v) gelatin incorporated
ink produced a more uniform filament shape than the 5% (w/v) gelatin incorporated ink. The filaments
also retained their shape without collapsing into each other. Therefore, the ink formulation of 2/3.5/7.5%
(w/v) alginate/gelatin/GelMA was selected for further experiments. To understand the effect of the gelatin
incorporation on ink’s flow behavior, rheology studies were performed comparing the 2/3.5/7.5% (w/v)
alginate/gelatin/GelMA ink and 2/7.5% (w/v) alginate/GelMA ink.

4.5. Rheological evaluation of the shell inks
Printable bioinks should be able to flow and retain their structure upon extrusion. The flow behaviors of
the inks were characterized by rheological tests. The rheological tests of the alginate/GelMA ink and
gelatin incorporated alginate/GelMA ink were compared to evaluate the gelatin incorporation to the ink’s
flow behavior. The flow behaviors of the inks were identified by an oscillatory temperature sweep, time
sweep, frequency sweep, strain sweep, rotational shear viscosity, and step strain tests.

Figure 24. Temperature sweep test of (A) 2/3.5/7.5% (w/v) alginate/gelatin/GelMA ink and
(B) 2/7.5% (w/v) alginate/GelMA ink. The data points represented in mean±sd (n=3).
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First, an oscillatory temperature sweep test identified the sol-gel transition temperature as gelatin is a
thermo-responsive biopolymer. Figure 24 presents the measured storage moduli (G’) and the loss moduli
(G”) of the ink plotted against the temperature. The storage modulus of the gelatin incorporated
alginate/GelMA ink measured 73 Pa, while the storage modulus of the alginate/GelMA ink measured 4.7
Pa at 22°C. This result indicated that incorporating 3.5% (w/v) gelatin increased the storage modulus of
2/7.5% (w/v) alginate/GelMA ink approximately 15 times. Furthermore, the sol-gel transition point where
the storage and loss modulus crossed were 21.3°C for alginate/gelatin/GelMA ink (Figure 24A) and 13.8°C
for alginate/GelMA ink (Figure 24B). This result suggested that incorporating gelatin made the
gelatin/GelMA ink transition from liquid to gel state at a higher temperature.
Second, gelation kinetics of the inks were also assessed through a time sweep test. Figure 25 presents the
gelatin incorporated alginate/GelMA and alginate/GelMA inks’ measured storage modulus plotted against
their gelation time. The alginate/GelMA ink reached its gel state in 160 seconds at 15°C, and the storage
modulus measured 54 Pa (Figure 25B). However, at 22.5°C, the alginate/GelMA ink was completely in a
liquid state. This state was indicated by the high loss modulus and low storage modulus (G”>G’). On the
other hand, the gelatin incorporated alginate/GelMA ink was already in a gelled state (G”<G’) at 22.5°C,
and the storage modulus measured 55 Pa (Figure 25A). This result suggested that gelation time was
significantly reduced by gelatin incorporation to the alginate/GelMA ink. To further understand the
viscoelastic behavior of the inks, the storage and loss modulus were measured with respect to frequency
and strain stress.

Figure 25. Time sweep test of (A) 2/3.5/7.5% (w/v) alginate/gelatin/GelMA ink and 2/7.5% (w/v)
alginate/GelMA ink at 22.5°C and (B) 2/7.5% (w/v) alginate/GelMA ink at 15°C. The data points
represented in mean±sd (n=3).

Third, the frequency sweep test measured the frequency dependency of the inks. The frequency sweep
measured the bioink’s storage and loss modulus with a range of frequencies (0.1-100Hz). The
alginate/gelatin/GelMA and alginate/GelMA inks showed frequency-dependent behavior (Figure 26). The
alginate/GelMA ink showed similar behavior at 15°C and 22.5°C, where the loss modulus was measured
higher than the storage modulus (G”>G’). The alginate/GelMA ink’s storage modulus measured 4.7 Pa,
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while gelatin incorporated alginate/GelMA ink’s storage modulus measured 73.8 Pa at 22.5°C and 0.1 Hz.
This measurement indicated that gelatin incorporation increased the storage modulus of the
alginate/GelMA ink about 15 times. This result was also reported from the temperature sweep test.

Figure 26. Frequency sweep test of (A) 2/3.5/7.5% (w/v) alginate/gelatin/GelMA ink and 2/7.5%
(w/v) alginate/GelMA ink at 22.5°C and (B) 2/7.5% (w/v) alginate/GelMA ink at 15°C. The data
points represented in mean±sd (n=3).

Fourth, the strain sweep test measured the limit of the polymer's ability to retain its three-dimensional
microstructure [50, 51]. The storage and loss modulus of alginate/GelMA ink were close to each other at
15°C (Figure 27B), while the storage modulus was much lower than loss modulus (G”>G’) at 22.5°C
(Figure 27A). This measurement indicated that the alginate/GelMA ink was in a liquid state at 22.5°C.

Figure 27. Strain sweep test of (A) 2/3.5/7.5% (w/v) alginate/gelatin/GelMA ink and 2/7.5% (w/v)
alginate/GelMA ink at 22.5°C and (B) 2/7.5% (w/v) alginate/GelMA ink at 15°C. The data points
represented in mean±sd (n=3).

In contrast, the storage and loss modulus of gelatin incorporated alginate/GelMA ink were measured at
proximity to each other at 22.5°C (Figure 27A). This proximity of storage (G’) and loss (G”) modulus
suggested that the ink was “at the gel point” where it behaved in-between gel and liquid [51]. The critical
strain value where the polymer network went under deformation (G’ = G”) for gelatin incorporated
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alginate/GelMA ink measured 127.23% of strain while alginate/GelMA ink measured 80.24% strain. A
possible explanation for the increase in the critical strain value is the entanglement and interaction of
gelatin with the alginate and GelMA molecules, thereby re-enforcing the polymer network against the
strain stress.
One of the important characteristics of ink for an extrusion-based application is its shear thinning property.
A shear-thinning material decreases in viscosity with increasing shear stress, allowing the bioink to flow
more freely under high shear stress. This property is beneficial for encapsulated cells since high shear
stress could rupture the cell’s membrane, which could cause irreversible damage [52]. The gelatin
incorporated alginate/GelMA (measured at 22.5°C) and alginate/GelMA (measured at 22.5°C and 15°C)
inks both showed shear-thinning behavior, which is defined as decreasing viscosity with increasing shear
stress (Figure 28A and Figure 28B). The relationship between the shear rate and the viscosity can be
explained through the power law equation:
𝜂𝜂 = 𝐾𝐾𝛾𝛾 𝑛𝑛−1

(12)

where η is viscosity (Pa.s), γ is a shear rate (s-1), n is the flow index, and K is the consistency index
(dimensionless) [53]. The consistency index (K) for alginate/gelatin/GelMA ink was 125, whereas
alginate/GelMA ink was 51.5. The consistency index reflects on the viscosity of the ink at zero shear (at
rest), and the high consistency index means more viscous bioink [47]. The flow index (n) for the
alginate/gelatin/GelMA ink was 0.257, whereas the alginate/GelMA ink was 0.466. The flow index reflects
on the shear-thinning characteristics, and the closer the value of n to zero, the higher the shear-thinning

Figure 28. Rotational shear viscosity test of (A) 2/3.5/7.5% (w/v) alginate/gelatin/GelMA ink and
2/7.5% (w/v) alginate/GelMA ink at 22.5°C and (B) 2/7.5% (w/v) alginate/GelMA ink at 15°C. The
data points represented in mean±sd (n=3).
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behavior of the ink [53]. Based on the flow and consistency indexes, the gelatin incorporated
alginate/GelMA ink was more viscous and higher shear-thinning than the alginate/GelMA ink.

Figure 29. Step strain test to determine the self-recovery of (A) 2/3.5/7.5% (w/v) alginate/gelatin/GelMA
ink and 2/7.5% (w/v) alginate/GelMA ink at 22.5°C and (B) 2/7.5% (w/v) alginate/GelMA ink at 15°C.
The inks were evaluated by low (0.1%) and high (1000%) cyclical strains for 28 minutes. The data
points represented in mean±sd (n=3).

Another important characteristic of the ink to be considered for extrusion-based bioprinting is its ability to
recover the polymer network after removing shear stress. This property is also known as self-recovery and
was assessed here by the step strain test. The bioinks were subjected to a low strain of 0.1% to represent
the ink at rest and a high strain of 1000% to mimic the stress exerted by the extrusion process to simulate
the printing environment. Figure 29A presents the self-recovery of alginate/gelatin/GelMA ink and
alginate/GelMA ink at 22.5°C. Figure 29B presents the self-recovery of the alginate/GelMA ink at 15°C.
The storage modulus (G’) was recorded as a function of time while going under high and low strain stresses
during the experiment. The alginate/gelatin/GelMA and alginate/GelMA inks showed rapid recovery after
experiencing high strain stress at 22.5°C and 15°C, respectively. During the first cycle, the storage modulus
of alginate/gelatin/GelMA ink decreased from an average value of 142 Pa to 2 Pa when the strain changed
from 0.1% to 1000%. During the subsequent seven cycles following the first cycle, the storage modulus
recovered by 97±24% to its initial value within 13 seconds.
On the other hand, the storage modulus of the alginate/GelMA ink decreased from the initial value of 121
Pa to 7.4 Pa in the first cycle when the strain changed from 0.1% to 1000%. During the subsequent seven
cycles following the first cycle, the storage modulus increased 173±16% of its initial value within 13
seconds. This over-increase of storage modulus was likely a result of increased molecular entanglement
from a lack of gelatin presence in the alginate/GelMA ink. In addition, the alginate/GelMA ink also showed
self-recovery behavior at 22.5°C. The storage modulus decreased from 0.5 Pa to 0.07 Pa when the strain
changed from 0.1% to 1000%. After the initial first cycle, the alginate/GelMA ink recovered its initial
value to 146±54% on average within 6 seconds at 22.5°C during the subsequent seven cycles.
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In summary, both inks demonstrated self-recovery behaviors, and the incorporation of 3.5% (w/v) gelatin
to the 2/7.5% (w/v) alginate/GelMA ink enhanced the polymer networking and viscoelastic property of the
ink.

4.6. Optimization of the core ink for coaxial bioprinting
The shell ink formulation of 2/3.5/7.5% (w/v) alginate/gelatin/GelMA was selected for the fabrication of
3D constructs. The core ink was developed to be reactive to the shell ink by replacing the alginate
component with the Ca2+ ions to improve the coaxial printing resolution. The core ink was formulated by
dissolving 3.5/7.5% (w/v) gelatin/GelMA in 50 mM CaCl2. Confocal imaging was utilized to visualize the
3D printed core and shell structures. To do so, FITC labeled GelMA was incorporated in the shell ink, and
rhodamine B labeled GelMA was incorporated in the core ink. Figure 30A presents the single coaxial layer
construct where the core was composed of rhodamine B labeled 2/3.5/7.5% (w/v) alginate/gelatin/GelMA
ink, and the shell was composed of FITC labeled 2/3.5/7.5% (w/v) alginate/gelatin/GelMA ink. The
corresponding confocal top and cross-sectional images suggested that the core and shell filament merged,
forming a hybrid filament as indicated by the colocalization of red and green fluorescent signals.
In contrast, Figure 30B presents the single coaxial layer construct where the core was composed of
rhodamine B labeled 3.5/7.5% (w/v) gelatin/GelMA ink dissolved in 50 mM CaCl2, and the shell was
composed of FITC labeled 2/3.5/7.5% (w/v) alginate/gelatin/GelMA ink. The filament showed a distinct
core and shell structure. This distinction was attributed to the ionic crosslinking between the alginate in
the shell ink and the Ca2+ in the core ink that immobilized the core and shell structure and contributed to
an improved resolution.

A

B

Figure 30. Resolution of coaxial lattices fabricated with (A) 2/3.5/7.5% (w/v)
alginate/gelatin/GelMA bioink in the core/shell fiber and (B) 3.5/7.5% (w/v) gelatin/GelMA
dissolved in 50 mM CaCl2 as a core and 2/3.5/7.5% (w/v) alginate/gelatin/GelMA as the shell ink.
Scale bar 200 µm.
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Viscosity assessment of the core ink
The core ink was subjected to a rotational shear viscosity test to evaluate the effect of microsphere
incorporation on the core ink. This experiment was performed to ensure the incorporation of microspheres
did not interfere with the ink’s flow behavior and, specifically, its shear-thinning behavior during the
printing process. The VEGF-A165 laden PLGA microspheres were mixed to the core ink with a
concentration of 10 mg/mL. The core ink’s flow profile with and without microsphere incorporation
showed shear thinning characteristics, shown in Figure 31A and Figure 31B. The viscosity and the shear
rate relationship of the core ink was fitted into the power-law model:
(12)

𝜂𝜂 = 𝐾𝐾𝛾𝛾 𝑛𝑛−1

where η is viscosity (Pa.s), γ is shear rate ( s-1), n is the flow index (dimensionless), and K is the consistency
index (dimensionless) [53]. The consistency index (K) value for the microsphere incorporated core ink was
17, while non-incorporated core ink was 24. When compared to the shell ink consistency index value
(K=125) the core ink with and without microspheres was less viscous; therefore easier for it to flow
through the nozzle. The flow index (n) value for microsphere incorporated core ink was 0.3, and nonincorporated core ink was 0.27. When compared to the shell ink’s flow index value (n=0.26), the core ink
with and without microsphere incorporation showed the same degree of shear-thinning behavior.

Figure 31. Shear viscosity assessment test of (A) 3.5/7.5% w/v gelatin/GelMA dissolved in 50 mM CaCl2 and
(B) 3.5/7.5% w/v gelatin/GelMA dissolved in 50 mM CaCl2 mixed with 10 mg/mL PLGA microspheres. The
data points represented in mean±sd (n=3).

This shear-thinning behavior indicated that both core and shell inks were high in shear-thinning. The result
suggested that incorporating VEGF-A165 laden PLGA microspheres did not interfere with the shearthinning behavior of the core ink. Figure 32 presents the microspheres dispersion in the core section of the
filaments when microsphere-laden core ink was printed along with the shell ink.

53

Figure 32. Microsphere distribution in the core channel of the two-layer lattice. The printing conditions
were set with an extrusion rate of 0.33 µl/mm, a speed of 100 mm/min, a filament spacing of 2.5 mm and a
core/shell ratio of 1/3. The rhodamine B labeled microspheres were incorporated in the core ink with a
concentration of 10 mg/mL. Scale bar 100 µm.
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4.7. Physicochemical property of 3D coaxial scaffolds
The 3D constructs fabricated with the shell ink formulation of 2/3.5/7.5% (w/v) alginate/gelatin/GelMA
and core ink formulation of 3.5/7.5% (w/v) gelatin/GelMA dissolved in 50 mM CaCl2 were shown in
Figure 33. The printing parameters were set at an extrusion rate of 0.33 µl/mm, a speed of 100 mm/min, a
core/shell ratio of 1/3, a filament spacing of 1.67 mm, and a dimension of 1 cm x 1 cm. The resulting four
layers of the printed lattice were 3.5±0.04 mm tall and weighed 329±2.6 µg. The photo and physically
crosslinked 3D constructs were subjected to a compression test and a water uptake study to understand
their physicochemical properties.

Figure 33. 3D construct fabricated with 2/3.5/7.5% (w/v) alginate/gelatin/GelMA shell ink and the
core ink of 3.5/7.5% (w/v) gelatin/GelMA dissolved in 50 mM CaCl2. The printing parameters were set
at an extrusion rate of 0.33 µl/mm, a speed of 100 mm/min, a core/shell ratio of 1/3 and a filament
spacing of 1.67 mm. The 4 layers of printed lattice’s dimensions were 1 cm x 1 cm in length, 3.5±0.04
mm in height. For visualization the core bioink was dyed with a red food dye.
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Water uptake study
The water uptake study defines the water retention ability of the 3D constructs, and higher rehydration
could also indicate a higher capacity of nutrition exchange and transportation. In general, the hydration
process starts with the water molecules first absorbed by the hydrophilic portion of the biopolymer
molecules, causing the polymer network to swell. This hydration further exposes the hydrophobic portion
of the polymer molecules. This created “bound water” where the water molecules were trapped between
the hydrophilic and hydrophobic parts [54]. Furthermore, additional water molecules would also fill the
space between the polymer networks in “free water” [54]. The swelling of hydrogel ends when the bound
and free water molecules reach an equilibrium [54]. The water uptake study was performed on two designs
of 3D constructs fabricated with the same printing parameters except different filament spacing. The first
design of the 3D construct was fabricated with a filament spacing of 2.5 mm, and the second design was
printed with a filament spacing of 1.67 mm. The 3D constructs fabricated with a filament spacing of 1.67
mm had a denser polymer network than the 3D constructs fabricated with a filament spacing of 2.5 mm
where water molecules might have difficulty penetrating. The water uptake of the 3D constructs with two
different filaments spacing was shown in Figure 34. The 3D constructs fabricated with a filament spacing
of 1.67 mm had increased 510±48% in the first hour, 764±74% in 3 hours, and increased to 1029±55% of
its initial weight within 24 hours. In contrast, the 3D constructs fabricated with a filament spacing of 2.5
mm increased 583±37% in the first hour, 833±6% in three hours, and increased to 997±81% of its initial
weight within 24 hours. The 3D constructs fabricated with a filament spacing of 2.5 mm rehydrated slightly
faster than the 3D constructs fabricated with a filament spacing of 1.67 mm, though the equilibrium water
content is similar for both constructs.

Figure 34. Rehydration rate of 3D constructs. Red line represents the water uptake capacity of
3D constructs fabricated with a filament spacing of 2.5 mm. Black line represents the water
uptake capacity of 3D constructs fabricated with a filament spacing of 1.67 mm. The data points
represented in mean±sd (n=3).
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Uniaxial Compression test
The fabricated scaffold should possess similar mechanical strength (stiffness) as the tissue of interest for a
successful bioprinting application. Stiffness is an object’s ability to resist deformation against the applied
force. Depending on the application, different tissues require different stiffness; for example, hard tissues
like bone require 1-2 gigapascal (GPa) and soft tissues like the brain require 0.1-10 kilopascal (kPa) [55].
The target tissue of interest for our projects is the islet which can be classified as a soft tissue [55]. A study
by Naujok et al. (2013) determined the pancreas tissue stiffness (Young’s modulus) from 9-week old
BALB/c mice measured 3100±327 Pa [56]. The Young’s modulus of the mice's pancreatic tissue was
measured using a creep meter Rheometer II (Yamaden, Japan) [56].
The 3D constructs’ Young’s modulus was evaluated by uniaxial compression tests over four weeks. The
samples were first removed from the media and compressed between two plates. The ultimate compressive
modulus was defined by the maximum force the 3D construct could bear before disintegrating. Figure 35A
presents the measured ultimate compressive modulus of the 3D constructs over four weeks. The ultimate
compressive modulus measured 56.5±3.3 kPa after one week, 42.2±0.6 kPA after two weeks, 28.2±1.9
kPA after three weeks, and 28.7±0.3 kPa after four weeks.

Figure 35. Mechanical strength of the 3D printed structures in vitro. (A). Stress-strain curve of
compressive strength (B). Young modulus calculated from 10-15% strain range from the stress-strain
curve. (C). Morphology of 3D printed structure after physical and photo-crosslinking (D) Morphology
of 3D printed structure after 28 days in vitro. The data points represented in mean±sd (n=3).
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The maximum strain was consistently within 52-58% at each weekly measurement. Young’s modulus was
calculated from the 10-15% strain range on the stress-strain curve. Figure 35B presents Young’s moduli
of the 3D constructs each week for four weeks. The Young’s modulus calculated 31.9±4.3 kPa in the first
week, 23.6±2.9 kPa in the second week, 21.4±2.7 kPa in the third week, and 14.5±0.5 kPa in the fourth
week. The dilution of gelatin and decrosslinking of alginate as a result of ion exchange with the culture
media attributed to a decrease of Young’s modulus each week. The 3D construct’s morphological change
from day 0 to day 28 was shown in Figures 35C and 35D, respectively. However, further studies such as
mass loss are required to measure mechanical strength decrease in relation to gelatin and alginate
dissolution and how it affects the cellular response to the 3D constructs.

4.8. VEGF-A165 release behavior from the 3D coaxial scaffold
The microsphere-mediated growth factor release was incorporated into the 3D constructs to improve the
biological property of the bioinks. The VEGF-A165 was chosen for this study to improve the angiogenic
property of the bioinks. The microspheres were incorporated in the core ink with a concentration of 10
mg/mL. The incorporated microsphere amount in the 3D construct was determined by calculating the core
amount from the 3D construct’s weight, assuming the core and shell ratios remained true during the
printing process—the 3D construct contained on average 0.95 mg of microspheres. The VEGF-A165
release behavior from the microsphere incorporated 3D constructs was assessed in vitro over four weeks.
The resulting VEGF-A165 release behavior from microsphere incorporated 3D constructs was then
compared with the VEGF-A165 release from the microspheres and the 3D constructs.

Figure 36. The VEGF-A165 release behavior from the microsphere incorporated 3D constructs
compared to the VEGF-A165 release behavior from the microspheres. The red line presents the VEGFA165 release behavior from the microsphere incorporated 3D constructs. The black line represents the
VEGF-A165 release behavior from the microspheres. The data points represent in mean±sd. (n=3)

Figure 36 presents the comparison of VEGF-A165 release from the microsphere incorporated 3D
constructs versus VEGF-A165 release directly from the microspheres. On the first day, 0.65 ng/mg of
VEGF-A165 release was detected from the microsphere incorporated 3D constructs. This VEGF-A165
release amount was 17-times lower than VEGF-A165 release directly from the microspheres. On day three,
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0.88 ng/mg of VEGF-A165 was measured, and on day seven, 0.08 ng/mg of VEGF-A165 was measured.
However, there was no detectable VEGF-A165 release measured from the microsphere incorporated 3D
constructs after day seven.
This VEGF-A165 release behavior from the microsphere incorporated 3D constructs was consistent with
VEGF-A165 release behavior from the microspheres where the VEGF-A165 release was significantly
dropped following the burst release. Unlike VEGF-A165 release directly from the microspheres, VEGFA165 release from the microsphere incorporated 3D constructs first released from the microspheres then
diffused through the 3D constructs, which contributed to a delayed VEGF-A165 release detection. Figure
37 presents the schematic illustration of the VEGF-A165 release pathway from the microsphere
incorporated 3D constructs.

Figure 37. Schematic illustration of VEGF-A165 release pathway from the microsphere
incorporated 3D constructs. The VEGF-A165 first released from the microspheres and them
diffused through the 3D construct’s matrix to the release media.

Figure 38 presents the comparison of VEGF-A165 release from the microsphere incorporated 3D
constructs versus VEGF-A165 release from the 3D constructs. The VEGF-A165 release from the
microsphere incorporated 3D constructs measured 1.2 ng/mL on the first day, 2.7 ng/mL on day three, and
2.9 ng/mL on day seven. After the seventh day, there was no detectable VEGF-A165 release from the
microsphere incorporated 3D constructs. On the other hand, VEGF-A165 release directly from the 3D
printed constructs was detectable over four weeks. The VEGF-A165 release directly from the 3D
constructs measured 1.7 ng/mL on day one, 3.8 ng/mL on day three, and 5.1 ng/mL on day seven. Similar

Figure 38. The VEGF-A165 release behavior from the microsphere incorporated 3D constructs
compared to the VEGF-A165 release behavior from the 3D constructs. Red line presents the VEGFA165 release from the microsphere incorporated 3D constructs. Black line presents the VEGF-A165
release from the 3D constructs. The data points represented in mean±sd (n=3).
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to the other VEGF-A165 release studies, after day seven, the VEGF-A165 release was significantly
decreased from the 3D constructs and resulted in a cumulative of 5.7 ng/mL VEGF-A165 release over four
weeks.

Figure 39. Schematic illustration of VEGF-A165 release pathway from the 3D
constructs. The VEGF-A165 diffused through the 3D construct’s matrix to the release
media.

Unlike VEGF-A165 release from the microsphere incorporated 3D constructs, VEGF-A165 release from
the 3D constructs diffused through the 3D construct’s matrix. This diffusion was attributed to a detectable
release over four weeks. Figure 39 presents the schematic illustration of the VEGF-A165 travel pathway
from the 3D constructs. However, the VEGF-A165 release directly from the 3D constructs or VEGF-A165
release from the microsphere incorporated 3D constructs was insufficient for the VEGF-A165
concentration (25-100 ng/mL) required for the re-vascularization process, which was reported from other
studies [28-31].
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5. Conclusion and future prospects
The price of insulin has increased by over 686% since 2001, and globally 76 billion dollars is spent on
type-1 diabetes per year [57]. Islet transplantation offers optimal glucose control without the round-theclock exogenous insulin administration. It involves a surgical procedure where the cadaver-sourced islets
are transplanted into the patients. However, several challenges, including donor shortage, immune reaction,
and premature graft failure, limit its widespread application. A coaxial bioprinting platform for pancreatic
tissue engineering could address the challenges associated with islet transplantation. The filaments
produced by a well-defined core and shell structure allow multiple cell types to be printed simultaneously.
Incorporating T-regulatory and endothelial cells into the filament can improve the function and survival of
the islet cells. Furthermore, incorporating biologically active molecules into filaments can further facilitate
islet revascularization and protection against the immune reaction.
This project focused on developing bioinks that will be utilized for coaxial printing for islets and their
supporting cells. The shell ink was formulated as 2/3.5/7.5% (w/v) alginate/gelatin/GelMA and the core
ink was formulated as 3.5/7.5% (w/v) gelatin/GelMA dissolved in 50 mM CaCl2. The core ink was
formulated to react with the shell ink through physical crosslinking to enhance the core and shell structure.
The 3D constructs printed with the core and shell inks showed structural stability over four weeks. The
vascular endothelial growth factor-A165 (VEGF-A165) laden PLGA microspheres were also explored to
aid the revascularization process. However, a cumulative of 2.9 ng/mL of VEGF-A165 release was
measured by ELISA from the microsphere incorporated 3D constructs. This result was insufficient for 3D
angiogenic studies reported by other studies where the VEGF-A165 concentration varied between 25-100
ng/mL [28-31]. As a next step, consideration should be made to other alternatives of sustained delivery
methods. For example, incorporating VEGF-A165 into GelMA microspheres could be more beneficial
than PLGA microspheres since the GelMA contains the cell attachment motif of Arg-Gly-Asp (RGD) [58].
Future research into the proliferation and migration of morphologically and phenotypically viable
encapsulated cells is essential for the next steps. A preliminary study reported by Kim et al. (2020) showed
that murine islet and human T-regulatory cells co-encapsulated with shell ink showed protection against
peripheral blood mononuclear cells (PMBC) over a week when supplemented by CCL1 and IL2, Tregulatory cell-specific bioactive factors [32]. A longer-term in vitro study is also required to examine
encapsulated islets' functions and understand their interactions with Tregs and EPCs.
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